Sripal Bangalore

List of Publications by Year
in descending order

Source: https://exaly.com/author-pdf/2148011/publications.pdf

Version: 2024-02-01

		5248	7333
604	29,579	83	152
papers	citations	h-index	g-index

662	662	662	28875
all docs	docs citations	times ranked	citing authors

#	Article	IF	Citations
1	Initial Invasive or Conservative Strategy for Stable Coronary Disease. New England Journal of Medicine, 2020, 382, 1395-1407.	13.9	1,508
2	Reninâ€“Angiotensinâ€“Aldosterone System Inhibitors and Risk of Covid-19. New England Journal of Medicine, 2020, 382, 2441-2448.	13.9	929
3	Fixed-Dose Combinations Improve Medication Compliance: A Meta-Analysis. American Journal of Medicine, 2007, 120, 713-719.	0.6	900
4	ST-Segment Elevation in Patients with Covid-19 â€" A Case Series. New England Journal of Medicine, 2020, 382, 2478-2480.	13.9	688
5	Extracorporeal membrane oxygenation support in COVID-19: an international cohort study of the Extracorporeal Life Support Organization registry. Lancet, The, 2020, 396, 1071-1078.	6.3	656
6	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization. Journal of the American College of Cardiology, 2022, 79, e21-e129.	1.2	561
7	Endovascular ultrasound renal denervation to treat hypertension (RADIANCE-HTN SOLO): a multicentre, international, single-blind, randomised, sham-controlled trial. Lancet, The, 2018, 391, 2335-2345.	6.3	526
8	Short- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents. Circulation, 2012, 125, 2873-2891.	1.6	521
9	Obesity Paradox in Patients with Hypertension and Coronary Artery Disease. American Journal of Medicine, 2007, 120, 863-870.	0.6	477
10	Diabetes and Hypertension: A Position Statement by the American Diabetes Association. Diabetes Care, 2017, 40, 1273-1284.	4.3	462
11	Atrial fibrillation and obesityâ€"results of a meta-analysis. American Heart Journal, 2008, 155, 310-315.	1.2	417
12	Chronic Kidney Disease and CoronaryÂArtery Disease. Journal of the American College of Cardiology, 2019, 74, 1823-1838.	1.2	403
13	Blood Pressure Targets in Subjects With Type 2 Diabetes Mellitus/Impaired Fasting Glucose. Circulation, 2011, 123, 2799-2810.	1.6	397
14	Î²-Blocker Use and Clinical Outcomes in Stable Outpatients With and Without Coronary Artery Disease. JAMA - Journal of the American Medical Association, 2012, 308, 1340.	3.8	377
15	Perioperative Î² blockers in patients having non-cardiac surgery: a meta-analysis. Lancet, The, 2008, 372, 1962-1976.	6.3	344
16	Antihypertensive drugs and risk of cancer: network meta-analyses and trial sequential analyses of 324â€ˆ168 participants from randomised trials. Lancet Oncology, The, 2011, 12, 65-82.	5.1	332
17	J-curve revisited: an analysis of blood pressure and cardiovascular events in the Treating to New Targets (TNT) Trial. European Heart Journal, 2010, 31, 2897-2908.	1.0	318
18	Management of Coronary Disease in Patients with Advanced Kidney Disease. New England Journal of Medicine, 2020, 382, 1608-1618.	13.9	310

#	Article	IF	Citations
19	The Transition From Hypertension toÂHeartÂFailure. JACC: Heart Failure, 2017, 5, 543-551.	1.9	305
20	Health-Status Outcomes with Invasive or Conservative Care in Coronary Disease. New England Journal of Medicine, 2020, 382, 1408-1419.	13.9	287
21	Perioperative Major Adverse Cardiovascular and Cerebrovascular Events Associated With Noncardiac Surgery. JAMA Cardiology, 2017, 2, 181.	3.0	268
22	Bare metal stents, durable polymer drug eluting stents, and biodegradable polymer drug eluting stents for coronary artery disease: mixed treatment comparison meta-analysis. BMJ, The, 2013, 347, f6625-f6625.	3.0	257
23	Everolimus-Eluting Stents or Bypass Surgery for Multivessel Coronary Disease. New England Journal of Medicine, 2015, 372, 1213-1222.	13.9	245
24	Statin therapy and long-term adverse limb outcomes in patients with peripheral artery disease: insights from the REACH registry. European Heart Journal, 2014, 35, 2864-2872.	1.0	238
25	A Meta-Analysis of 94,492 Patients With Hypertension Treated With Beta Blockers to Determine the Risk of New-Onset Diabetes Mellitus. American Journal of Cardiology, 2007, 100, 1254-1262.	0.7	232
26	Body-Weight Fluctuations and Outcomes in Coronary Disease. New England Journal of Medicine, 2017, 376, 1332-1340.	13.9	229
27	Clinical Outcomes with Î²-Blockers for Myocardial Infarction: A Meta-analysis of Randomized Trials. American Journal of Medicine, 2014, 127, 939-953.	0.6	224
28	Angiotensin-Converting Enzyme Inhibitors in Hypertension. Journal of the American College of Cardiology, 2018, 71, 1474-1482.	1.2	215
29	Cardiovascular Protection Using Beta-Blockers. Journal of the American College of Cardiology, 2007, 50, 563-572.	1.2	214
30	What Is the Optimal Blood Pressure in Patients After Acute Coronary Syndromes?. Circulation, 2010, 122, 2142-2151.	1.6	207
31	Newer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease. Circulation, 2018, 138, 2216-2226.	1.6	206
32	International Study of Comparative Health Effectiveness with Medical and Invasive Approaches (ISCHEMIA) trial: Rationale and design. American Heart Journal, 2018, 201, 124-135.	1.2	202
33	Ultrasound renal denervation for hypertension resistant to a triple medication pill (RADIANCE-HTN) Tj ETQq1 1 0.784314 rgBT /Overlock	6.3	197
34	Outcomes with various drug eluting or bare metal stents in patients with diabetes mellitus: mixed treatment comparison analysis of 22 844 patient years of follow-up from randomised trials. BMJ, The, 2012, 345, e5170-e5170.	3.0	196
35	Treatment-Resistant Hypertension and the Incidence of Cardiovascular Disease and End-Stage Renal Disease. Hypertension, 2014, 64, 1012-1021.	1.3	196
36	Temporal Trends and Outcomes ofÂPatients Undergoing Percutaneous Coronary Interventions for Cardiogenic Shock in the Setting of Acute MyocardialÂInfarction. JACC: Cardiovascular Interventions, 2016, 9, 341-351.	1.1	194

#	Article	IF	Citations
37	Relation of Beta-Blockerâ€“Induced Heart Rate Lowering and Cardioprotection in Hypertension. Journal of the American College of Cardiology, 2008, 52, 1482-1489.	1.2	191
38	Percutaneous Coronary Intervention Versus Optimal Medical Therapy in Stable Coronary Artery Disease. Circulation: Cardiovascular Interventions, 2012, 5, 476-490.	1.4	189
39	Efficacy and safety of dual blockade of the renin-angiotensin system: meta-analysis of randomised trials. BMJ, The, 2013, 346, f360-f360.	3.0	185
40	Machine learning prediction in cardiovascular diseases: a meta-analysis. Scientific Reports, 2020, 10, 16057.	1.6	182
41	Coronary Optical Coherence Tomography and Cardiac Magnetic Resonance Imaging to Determine Underlying Causes of Myocardial Infarction With Nonobstructive Coronary Arteries in Women. Circulation, 2021, 143, 624-640.	1.6	180
42	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001038.	1.6	177
43	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary: A Report of the American College of Cardiology/American Heart Association Joint Committee on Clinical Practice Guidelines. Circulation, 2022, 145, CIR0000000000001039.	1.6	159
44	Rationale and design of the dual antiplatelet therapy study, a prospective, multicenter, randomized, double-blind trial to assess the effectiveness and safety of 12 versus 30 months of dual antiplatelet therapy in subjects undergoing percutaneous coronary intervention with either drug-eluting stent or bare metal stent placement for the treatment of coronary artery lesions. American Heart Journal, 2010, 160, 1035-1041.e1.	1.2	158
45	Visit-to-Visit Low-Density Lipoprotein Cholesterol Variability and Risk of Cardiovascular Outcomes. Journal of the American College of Cardiology, 2015, 65, 1539-1548.	1.2	156
46	2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization: Executive Summary. Journal of the American College of Cardiology, 2022, 79, 197-215.	1.2	150
47	Antihypertensive Efficacy of Hydrochlorothiazide as Evaluated by Ambulatory Blood Pressure Monitoring. Journal of the American College of Cardiology, 2011, 57, 590-600.	1.2	148
48	Meta-Analysis of Randomized Trials of Angioedema as an Adverse Event of Reninâ€“Angiotensin System Inhibitors. American Journal of Cardiology, 2012, 110, 383-391.	0.7	145
49	Optimal Systolic Blood Pressure Target After SPRINT: Insights from a Network Meta-Analysis of Randomized Trials. American Journal of Medicine, 2017, 130, 707-719.e8.	0.6	142
50	Flash pulmonary oedema and bilateral renal artery stenosis: the Pickering Syndrome. European Heart Journal, 2011, 32, 2231-2235.	1.0	141
51	Role of Aspiration and Mechanical Thrombectomy in Patients With Acute Myocardial Infarction Undergoing PrimaryÂAngioplasty. Journal of the American College of Cardiology, 2013, 62, 1409-1418.	1.2	140
52	Outcomes in the ISCHEMIA Trial Based on Coronary Artery Disease and Ischemia Severity. Circulation, 2021, 144, 1024-1038.	1.6	140
53	Meta-Analysis of Randomized Clinical Trials Comparing Biodegradable Polymer Drug-Eluting Stent to Second-Generation Durable Polymer Drug-Eluting Stents. JACC: Cardiovascular Interventions, 2017, 10, 462-473.	1.1	138
54	Diabetes mellitus as a compelling indication for use of renin angiotensin system blockers: systematic review and meta-analysis of randomized trials. BMJ, The, 2016, 352, i438.	3.0	135

#	Article	IF	Citations
55	Age and Gender Differences in Quality of Care and Outcomes for Patients with ST-segment Elevation Myocardial Infarction. American Journal of Medicine, 2012, 125, 1000-1009.	0.6	128
56	Revascularization in Patients With Multivessel Coronary Artery Disease and Severe Left Ventricular Systolic Dysfunction. Circulation, 2016, 133, 2132-2140.	1.6	124
57	Angiotensin receptor blockers and risk of myocardial infarction: meta-analyses and trial sequential analyses of 147 020 patients from randomised trials. BMJ: British Medical Journal, 2011, 342, d2234-d2234.	2.4	121
58	Revascularization in Patients With MultivesselÂCoronary Artery Disease and ChronicÂKidneyÂDisease. Journal of the American College of Cardiology, 2015, 66, 1209-1220.	1.2	119
59	Prognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality. Circulation, 2014, 130, 546-553.	1.6	118
60	Routine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease. Circulation, 2020, 142, 841-857.	1.6	118
61	Risk/Benefit Assessment of Î²-Blockers and Diuretics Precludes Their Use for First-Line Therapy in Hypertension. Circulation, 2008, 117, 2706-2715.	1.6	117
62	Outcomes of Intensive Blood Pressure Lowering in Older Hypertensive Patients. Journal of the American College of Cardiology, 2017, 69, 486-493.	1.2	117
63	Oral Anticoagulation for Patients WithÂAtrial Fibrillation on Long-Term Dialysis. Journal of the American College of Cardiology, 2020, 75, 273-285.	1.2	117
64	Radiation exposure in relation to the arterial access site used for diagnostic coronary angiography and percutaneous coronary intervention: a systematic review and meta-analysis. Lancet, The, 2015, 386, 2192-2203.	6.3	115
65	Cardiovascular disease in the kidney transplant recipient: epidemiology, diagnosis and management strategies. Nephrology Dialysis Transplantation, 2019, 34, 760-773.	0.4	115
66	Effect of Renin-Angiotensin System Blockade on Calcium Channel Blocker-Associated Peripheral Edema. American Journal of Medicine, 2011, 124, 128-135.	0.6	109
67	A Randomized Comparison of the Transradial and Transfemoral Approaches for Coronary Artery Bypass Graft Angiography and Intervention. JACC: Cardiovascular Interventions, 2013, 6, 1138-1144.	1.1	108
68	Paclitaxel-Eluting versus Everolimus-Eluting Coronary Stents in Diabetes. New England Journal of Medicine, 2015, 373, 1709-1719.	13.9	106
69	Diagnosis and management of atherosclerotic cardiovascular disease in chronic kidney disease: aÂreview. Kidney International, 2017, 91, 797-807.	2.6	102
70	Baseline Characteristics and Risk Profiles of Participants in the ISCHEMIA Randomized Clinical Trial. JAMA Cardiology, 2019, 4, 273.	3.0	100
71	Chronic Inflammation in Chronic Kidney Disease Progression: Role of Nrf2. Kidney International Reports, 2021, 6, 1775-1787.	0.4	100
72	Long-Term Outcomes With TranscatheterÂAorticÂValve Replacement inÂWomenÂCompared With Men. JACC: Cardiovascular Interventions, 2018, 11, 24-35.	1.1	99

#	Article	IF	Citations
73	Perioperative acute myocardial infarction associated with non-cardiac surgery. European Heart Journal, 2017, 38, 2409-2417.	1.0	98
74	Changes in Lipid Profile of Obese Patients Following Contemporary Bariatric Surgery: AÂMeta-Analysis. American Journal of Medicine, 2016, 129, 952-959.	0.6	97
75	Six-Month Results of Treatment-Blinded Medication Titration for Hypertension Control After Randomization to Endovascular Ultrasound Renal Denervation or a Sham Procedure in the RADIANCE-HTN SOLO Trial. Circulation, 2019, 139, 2542-2553.	1.6	97
76	Body Weight Changes with Î²-Blocker Use: Results from GEMINI. American Journal of Medicine, 2007, 120, 610-615.	0.6	95
77	Angiographic success and procedural complications in patients undergoing retrograde percutaneous coronary chronic total occlusion interventions: A weighted meta-analysis of 3482 patients from 26 studies. International Journal of Cardiology, 2014, 174, 243-248.	0.8	95
78	Endothelial progenitor cell mobilization after percutaneous coronary intervention. Atherosclerosis, 2006, 189, 70-75.	0.4	94
79	Clinical Utility of the Japanâ€“Chronic Total Occlusion Score in Coronary Chronic Total Occlusion Interventions. Circulation: Cardiovascular Interventions, 2015, 8, e002171.	1.4	93
80	Comparison of local versus general anesthesia in patients undergoing transcatheter aortic valve replacement: A metaâ€analysis. Catheterization and Cardiovascular Interventions, 2018, 91, 330-342.	0.7	91
81	Beta-Blockers for Primary Prevention of Heart Failure in Patients With Hypertension. Journal of the American College of Cardiology, 2008, 52, 1062-1072.	1.2	90
82	Angiotensin-Converting Enzyme Inhibitor Associated Cough: Deceptive Information from the Physicians' Desk Reference. American Journal of Medicine, 2010, 123, 1016-1030.	0.6	90
83	Gun Ownership and Firearm-related Deaths. American Journal of Medicine, 2013, 126, 873-876.	0.6	88
84	Pulse pressure and risk of cardiovascular outcomes in patients with hypertension and coronary artery disease: an INternational VErapamil SR-trandolapril STudy (INVEST) analysis. European Heart Journal, 2009, 30, 1395-1401.	1.0	86
85	Angiotensin-Converting Enzyme Inhibitors or Angiotensin Receptor Blockers in Patients Without Heart Failure? Insights From 254,301 Patients From Randomized Trials. Mayo Clinic Proceedings, 2016, 91, 51-60.	1.4	86
86	Device Thrombosis After Percutaneous Left Atrial Appendage Occlusion Is Related to Patient and Procedural Characteristics but Not to Duration of Postimplantation Dual Antiplatelet Therapy. Circulation: Cardiovascular Interventions, 2018, 11, e005997.	1.4	86
87	Early intravenous beta-blockers in patients with acute coronary syndromeâ€”A meta-analysis of randomized trials. International Journal of Cardiology, 2013, 168, 915-921.	0.8	84
88	Î²-Blockers and Cardiovascular Events in Patients With and Without Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2014, 7, 872-881.	0.9	84
89	Percutaneous Coronary Intervention Versus Optimal Medical Therapy for Prevention of Spontaneous Myocardial Infarction in Subjects With Stable Ischemic Heart Disease. Circulation, 2013, 127, 769-781.	1.6	83
90	Myocardial Infarction in the ISCHEMIA Trial. Circulation, 2021, 143, 790-804.	1.6	81

#	Article	IF	Citations
91	Chronic kidney disease and valvular heart disease: conclusions from a Kidney Disease: Improving Global Outcomes (KDIGO) Controversies Conference. Kidney International, 2019, 96, 836-849.	2.6	80
92	Vascular Closure Device Failure: Frequency and Implications. Circulation: Cardiovascular Interventions, 2009, 2, 549-556.	1.4	79
93	The association of admission heart rate and in-hospital cardiovascular events in patients with non-ST-segment elevation acute coronary syndromes: results from 135 164 patients in the CRUSADE quality improvement initiative. European Heart Journal, 2010, 31, 552-560.	1.0	79
94	Peripheral edema associated with calcium channel blockers: incidence and withdrawal rate â€“ a meta-analysis of randomized trials. Journal of Hypertension, 2011, 29, 1270-1280.	0.3	79
95	Carotid Artery Stenting vs Carotid Endarterectomy. Archives of Neurology, 2011, 68, 172-84.	4.9	78
96	Acute Myocardial Infarction During Pregnancy and the Puerperium in the United States. Mayo Clinic Proceedings, 2018, 93, 1404-1414.	1.4	78
97	Prevalence, Predictors, and Outcomes in Treatment-resistant Hypertension in Patients with Coronary Disease. American Journal of Medicine, 2014, 127, 71-81.e1.	0.6	77
98	Complete Versus Culprit-Only Revascularization for ST-Segmentâ€“Elevation Myocardial Infarction and Multivessel Disease. Circulation: Cardiovascular Interventions, 2015, 8, .	1.4	75
99	Saphenous Vein Graft Failure: From Pathophysiology to Prevention and Treatment Strategies. Circulation, 2021, 144, 728-745.	1.6	75
100	Percutaneous coronary intervention of moderate to severe calcified coronary lesions: Insights from the National Heart, Lung, and Blood Institute Dynamic Registry. Catheterization and Cardiovascular Interventions, 2011, 77, 22-28.	0.7	73
101	Outcomes With Various Drug-Eluting or Bare Metal Stents in Patients With ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2013, 6, 378-390.	1.4	73
102	Outcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Patients With Diabetes Mellitus. Circulation: Cardiovascular Interventions, 2014, 7, 518-525.	1.4	72
103	Drug-eluting stents versus bare-metal stents in saphenous vein grafts: a double-blind, randomised trial. Lancet, The, 2018, 391, 1997-2007.	6.3	70
104	Impact of COVIDâ€19 pandemic on STEMI care: An expanded analysis from the United States. Catheterization and Cardiovascular Interventions, 2021, 98, 217-222.	0.7	70
105	Longâ€term cardiovascular mortality after radiotherapy for breast cancer: A systematic review and metaâ€analysis. Clinical Cardiology, 2017, 40, 73-81.	0.7	69
106	Renin angiotensin system inhibitors for patients with stable coronary artery disease without heart failure: systematic review and meta-analysis of randomized trials. BMJ: British Medical Journal, 2017, 356, j4.	2.4	69
107	2014 Eighth Joint National Committee Panel Recommendation for BloodÂPressureÂTargets Revisited. Journal of the American College of Cardiology, 2014, 64, 784-793.	1.2	67
108	Complications of Chronic Total Occlusion Angioplasty. Interventional Cardiology Clinics, 2012, 1, 373-389.	0.2	66

#	Article	IF	Citations
109	Meta-Analysis of Randomized Clinical Trials Comparing Short-Term Versus Long-Term Dual Antiplatelet Therapy Following Drug-Eluting Stents. American Journal of Cardiology, 2014, 114, 236-242.	0.7	66
110	Trends in cardiovascular risk factor and disease prevalence in patients undergoing non-cardiac surgery. Heart, 2018, 104, 1180-1186.	1.2	66
111	Meta-Analysis of Randomized Controlled Trials and Adjusted Observational Results of Use of Clopidogrel, Aspirin, and Oral Anticoagulants in Patients Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2015, 115, 1185-1193.	0.7	65
112	Risk of Noncardiac Surgery After Coronary Drug-Eluting Stent Implantation. American Journal of Cardiology, 2006, 98, 1212-1213.	0.7	64
113	Comparison of Baseline Characteristics, Treatment Patterns, and In-Hospital Outcomes of Asian Versus Non-Asian White Americans With Nonâ€“ST-Segment Elevation Acute Coronary Syndromes from the CRUSADE Quality Improvement Initiative. American Journal of Cardiology, 2007, 100, 391-396.	0.7	64
114	Cardiac rehabilitation fitness changes and subsequent survival. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 173-179.	1.8	64
115	Renal Denervation for Resistant Hypertension?. New England Journal of Medicine, 2014, 370, 1454-1457.	13.9	62
116	Future Direction for Using Artificial Intelligence to Predict and Manage Hypertension. Current Hypertension Reports, 2018, 20, 75.	1.5	62
117	Meta-Analysis of Multivessel Coronary Artery Revascularization Versus Culprit-Only Revascularization in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Disease. American Journal of Cardiology, 2011, 107, 1300-1310.	0.7	61
118	Femoropopliteal Artery Stent Thrombosis. Circulation: Cardiovascular Interventions, 2016, 9, e002730.	1.4	61
119	Meta-Analysis of Trials on Mortality After Percutaneous Coronary Intervention Compared With Medical Therapy in Patients With Stable Coronary Heart Disease and Objective Evidence of Myocardial Ischemia. American Journal of Cardiology, 2015, 115, 1194-1199.	0.7	60
120	Risk Factor Variability and CardiovascularÂOutcome. Journal of the American College of Cardiology, 2019, 73, 2596-2603.	1.2	60
121	Compliance and fixed-dose combination therapy. Current Hypertension Reports, 2007, 9, 184-189.	1.5	59
122	Half a Century of Hydrochlorothiazide: Facts, Fads, Fiction, and Follies. American Journal of Medicine, 2011, 124, 896-899.	0.6	59
123	No evidence for a J-shaped curve in treated hypertensive patients with increased cardiovascular risk: The VALUE trial. Blood Pressure, 2016, 25, 83-92.	0.7	59
124	Blood pressure targets in patients with coronary artery disease: observations from traditional and Bayesian random effects meta-analysis of randomised trials. Heart, 2013, 99, 601-613.	1.2	58
125	Relation of Variability of Low-Density Lipoprotein Cholesterol and Blood Pressure to Events in Patients With Previous Myocardial Infarction from the IDEAL Trial. American Journal of Cardiology, 2017, 119, 379-387.	0.7	58
126	Femoral Arterial Access and Closure. Circulation, 2011, 124, e147-56.	1.6	57

#	Article	IF	Citations
127	Meta-Analysis of Comparison of the Newer Oral P2Y12 Inhibitors (Prasugrel or Ticagrelor) to Clopidogrel in Patients With Nonâ€“ST-Elevation Acute Coronary Syndrome. American Journal of Cardiology, 2015, 116, 809-817.	0.7	56
128	Everolimus Eluting Stents Versus Coronary Artery Bypass Graft Surgery for Patients With Diabetes Mellitus and Multivessel Disease. Circulation: Cardiovascular Interventions, 2015, 8, e002626.	1.4	56
129	Use of Antiplatelet Therapy/DAPT forÂPost-PCI Patients Undergoing Noncardiac Surgery. Journal of the American College of Cardiology, 2017, 69, 1861-1870.	1.2	56
130	Comparative Efficacy of Endovascular Revascularization Versus Supervised Exercise Training in Patients With Intermittent Claudication. JACC: Cardiovascular Interventions, 2017, 10, 712-724.	1.1	56
131	Health Status after Invasive or Conservative Care in Coronary and Advanced Kidney Disease. New England Journal of Medicine, 2020, 382, 1619-1628.	13.9	56
132	3- or 1-Month DAPT in Patients at High Bleeding Risk Undergoing Everolimus-Eluting Stent Implantation. JACC: Cardiovascular Interventions, 2021, 14, 1870-1883.	1.1	56
133	Assessment of left atrial appendage function with transthoracic tissue Doppler echocardiography. European Journal of Echocardiography, 2009, 10, 363-371.	2.3	55
134	Wilder's principle: pre-treatment value determines post-treatment response. European Heart Journal, 2015, 36, 576-579.	1.0	55
135	The State of the Absorb BioresorbableÂScaffold. JACC: Cardiovascular Interventions, 2017, 10, 2349-2359.	1.1	55
136	Role of Left Atrial Size in Risk Stratification and Prognosis of Patients Undergoing Stress Echocardiography. Journal of the American College of Cardiology, 2007, 50, 1254-1262.	1.2	54
137	Cardiovascular Outcomes of Patients With Pulmonary Hypertension Undergoing Noncardiac Surgery. American Journal of Cardiology, 2019, 123, 1532-1537.	0.7	54
138	Association between Arsenic Exposure from Drinking Water and Longitudinal Change in Blood Pressure among HEALS Cohort Participants. Environmental Health Perspectives, 2015, 123, 806-812.	2.8	52
139	Revascularization Trends in Patients With Diabetes Mellitus and Multivessel Coronary Artery Disease Presenting With Nonâ€“ST Elevation Myocardial Infarction. Circulation: Cardiovascular Quality and Outcomes, 2016, 9, 197-205.	0.9	52
140	When an Increase in Central Systolic Pressure Overrides theÂBenefits ofÂHeartÂRate Lowering. Journal of the American College of Cardiology, 2016, 68, 754-762.	1.2	52
141	Blood pressure and in-hospital outcomes in patients presenting with ischaemic stroke. European Heart Journal, 2017, 38, 2827-2835.	1.0	51
142	Body Weight Variability and Cardiovascular Outcomes in Patients With Type 2 Diabetes Mellitus. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004724.	0.9	50
143	Short and long-term mortality in women and men undergoing primary angioplasty: A comprehensive meta-analysis. International Journal of Cardiology, 2015, 198, 123-130.	0.8	49
144	Verapamil-sustained releaseâ€“based treatment strategy is equivalent to atenolol-based treatment strategy at reducing cardiovascular events in patients with prior myocardial infarction: An INternational VErapamil SR-Trandolapril (INVEST) substudy. American Heart Journal, 2008, 156, 241-247.	1.2	48

#	Article	IF	Citations
145	Outcomes with Invasive vs Conservative Management of Cardiogenic Shock Complicating Acute Myocardial Infarction. American Journal of Medicine, 2015, 128, 601-608.	0.6	48
146	Role of Right Ventricular Wall Motion Abnormalities in Risk Stratification and Prognosis of Patients Referred for Stress Echocardiography. Journal of the American College of Cardiology, 2007, 50, 1981-1989.	1.2	47
147	Anticoagulant therapy during primary percutaneous coronary intervention for acute myocardial infarction: a meta-analysis of randomized trials in the era of stents and P2Y12 inhibitors. BMJ, The, 2014, 349, g6419-g6419.	3.0	47
148	Sodium intake, life expectancy, and all-cause mortality. European Heart Journal, 2021, 42, 2103-2112.	1.0	46
149	Long-term follow-up after ultrathin vs. conventional 2nd-generation drug-eluting stents: a systematic review and meta-analysis of randomized controlled trials. European Heart Journal, 2021, 42, 2643-2654.	1.0	46
150	Pilot Trial of Cryoplasty or Conventional Balloon Post-Dilation of Nitinol Stents for Revascularization of Peripheral Arterial Segments. Journal of the American College of Cardiology, 2012, 60, 1352-1359.	1.2	45
151	Vascular Closure Device Failure in Contemporary Practice. JACC: Cardiovascular Interventions, 2012, 5, 837-844.	1.1	45
152	Meta-Analysis of Cilostazol Versus Aspirin for the Secondary Prevention of Stroke. American Journal of Cardiology, 2013, 112, 1230-1234.	0.7	45
153	A meta-analysis and meta-regression of long-term outcomes of transcatheter versus surgical aortic valve replacement for severe aortic stenosis. International Journal of Cardiology, 2016, 225, 234-243.	0.8	45
154	Visit-to-visit variability of lipid measurements as predictors of cardiovascular events. Journal of Clinical Lipidology, 2018, 12, 356-366.	0.6	45
155	Alport Syndrome Classification and Management. Kidney Medicine, 2020, 2, 639-649.	1.0	45
156	Comparative Effectiveness of Angiotensin-Converting Enzyme Inhibitor-Based Treatment on Cardiovascular Outcomes in HypertensiveÂBlacks Versus Whites. Journal of the American College of Cardiology, 2015, 66, 1224-1233.	1.2	44
157	International Study of Comparative Health Effectiveness with Medical and Invasive Approachesâ€“Chronic Kidney Disease (ISCHEMIA-CKD): Rationale and design. American Heart Journal, 2018, 205, 42-52.	1.2	44
158	Radiation exposure during coronary angiography via transradial or transfemoral approaches when performed by experienced operators. American Heart Journal, 2013, 165, 286-292.	1.2	43
159	JetStream Rotational and Aspiration Atherectomy in Treating In-Stent Restenosis of the Femoropopliteal Arteries. Journal of Endovascular Therapy, 2016, 23, 339-346.	0.8	42
160	Risk Stratification Using Stress Echocardiography: Incremental Prognostic Value over Historic, Clinical, and Stress Electrocardiographic Variables Across a Wide Spectrum of Bayesian Pretest Probabilities for Coronary Artery Disease. Journal of the American Society of Echocardiography, 2007, 20, 244-252.	1.2	41
161	Outcomes of Saphenous Vein Graft Intervention With and Without Embolic Protection Device. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	41
162	Drug Delivering Technology for Endovascular Management of Infrainguinal Peripheral Artery Disease. JACC: Cardiovascular Interventions, 2014, 7, 827-839.	1.1	40

#	Article	IF	Citations
163	Resistant hypertension: what the cardiologist needs to know. European Heart Journal, 2015, 36, 2686-2695.	1.0	40
164	Major Limb Outcomes Following Lower Extremity Endovascular Revascularization in Patients With and Without Diabetes Mellitus. Journal of Endovascular Therapy, 2017, 24, 376-382.	0.8	40
165	Management and outcomes of acute myocardial infarction in patients with chronic kidney disease. International Journal of Cardiology, 2017, 227, 1-7.	0.8	40
166	Cardiac Outcomes With Submaximal Normal Stress Echocardiography. Journal of the American College of Cardiology, 2012, 60, 1393-1401.	1.2	39
167	Efficacy of cilostazol on platelet reactivity and cardiovascular outcomes in patients undergoing percutaneous coronary intervention: insights from a meta-analysis of randomised trials. Open Heart, 2014, 1, e000068.	0.9	39
168	Impact of Chronic Total Occlusions and Coronary Revascularization on All-Cause Mortality and the Incidence of Ventricular Arrhythmias in Patients With Ischemic Cardiomyopathy. American Journal of Cardiology, 2015, 116, 1358-1362.	0.7	39
169	Impact of Sex and Contactâ€toâ€Device Time on Clinical Outcomes in Acute STâ€Segment Elevation Myocardial Infarctionâ€"Findings From the National Cardiovascular Data Registry. Journal of the American Heart Association, 2017, 6, .	1.6	39
170	Duration of Dual Antiplatelet Therapy forÂPatients at High Bleeding Risk Undergoing PCI. Journal of the American College of Cardiology, 2021, 78, 2060-2072.	1.2	39
171	Renin Angiotensin Aldosterone System Inhibitors in Hypertension: Is There Evidence for Benefit Independent of Blood Pressure Reduction?. Progress in Cardiovascular Diseases, 2016, 59, 253-261.	1.6	38
172	Long-Acting Calcium Antagonists in Patients with Coronary Artery Disease: A Meta-Analysis. American Journal of Medicine, 2009, 122, 356-365.	0.6	37
173	Prognostic Implications of Stress Echocardiography and Impact on Patient Outcomes: An Effective Gatekeeper for Coronary Angiography and Revascularization. Journal of the American Society of Echocardiography, 2010, 23, 832-839.	1.2	37
174	Aspiration thrombectomy in patients undergoing primary angioplasty: Totality of data to 2013. Catheterization and Cardiovascular Interventions, 2014, 84, 973-977.	0.7	37
175	2013 Cholesterol Guidelines Revisited: Percent LDL Cholesterol Reduction or Attained LDL Cholesterol Level or Both for Prognosis?. American Journal of Medicine, 2016, 129, 384-391.	0.6	37
176	Complete vs Culprit-Only Percutaneous Coronary Intervention in STEMI With Multivessel Disease: A Meta-analysis and Trial Sequential Analysis of Randomized Trials. Canadian Journal of Cardiology, 2016, 32, 1542-1551.	0.8	37
177	CT Angiography Followed by Invasive Angiography in Patients With Moderate or Severe Ischemia-Insights From the ISCHEMIA Trial. JACC: Cardiovascular Imaging, 2021, 14, 1384-1393.	2.3	37
178	Statin and the Risk of Renal-Related Serious Adverse Events: Analysis from the IDEAL, TNT, CARDS, ASPEN, SPARCL, and Other Placebo-Controlled Trials. American Journal of Cardiology, 2014, 113, 2018-2020.	0.7	36
179	Accuracy of Remote Electrocardiogram Interpretation With the Use of Google Glass Technology. American Journal of Cardiology, 2015, 115, 374-377.	0.7	36
180	Comparative Assessment of Guidewire and Microcatheter vs a Crossing Deviceâ€"Based Strategy to Traverse Infrainguinal Peripheral Artery Chronic Total Occlusions. Journal of Endovascular Therapy, 2015, 22, 525-534.	0.8	36

#	Article	IF	Citations
181	COVIDâ€19 complicated by acute myocardial infarction with extensive thrombus burden and cardiogenic shock. Catheterization and Cardiovascular Interventions, 2021, 97, E661-E666.	0.7	35
182	Salt and heart disease: a second round of â€œbad scienceâ€?. Lancet, The, 2018, 392, 456-458.	6.3	33
183	Cardiovascular Safety of Potential Drugs for the Treatment of Coronavirus Disease 2019. American Journal of Cardiology, 2020, 128, 147-150.	0.7	33
184	Comparison of Prognostic Value of Stress Echocardiography Versus Stress Electrocardiography in Patients With Suspected Coronary Artery Disease. American Journal of Cardiology, 2005, 96, 628-634.	0.7	32
185	Trend in the use of drug eluting stents in the United States. International Journal of Cardiology, 2014, 175, 108-119.	0.8	32
186	Angiotensin Receptor Blockers Reduce Cardiovascular Events, Including the Risk of Myocardial Infarction. Circulation, 2017, 135, 2085-2087.	1.6	32
187	Fifteenâ€Year Trends in Management and Outcomes of Nonâ€“STâ€Segmentâ€“Elevation Myocardial Infarction Among Black and White Patients: The ARIC Community Surveillance Study, 2000â€“2014. Journal of the American Heart Association, 2018, 7, e010203.	1.6	32
188	The association between coronary graft patency and clinical status in patients with coronary artery disease. European Heart Journal, 2021, 42, 1433-1441.	1.0	32
189	Kidney Transplant List Status and Outcomes in the ISCHEMIA-CKD Trial. Journal of the American College of Cardiology, 2021, 78, 348-361.	1.2	32
190	Anomalous Right Coronary Artery and Sudden Cardiac Death. Circulation: Arrhythmia and Electrophysiology, 2012, 5, e111-2.	2.1	31
191	Study Design and Baseline Characteristics of the CARDINAL Trial: A Phase 3 Study of Bardoxolone Methyl in Patients with Alport Syndrome. American Journal of Nephrology, 2021, 52, 180-189.	1.4	31
192	Fixed combination of amlodipine and atorvastatin in cardiovascular risk management: patient perspectives. Vascular Health and Risk Management, 2009, 5, 377.	1.0	30
193	Evaluation and Management of Aortic Stenosis in Chronic Kidney Disease: A Scientific Statement From the American Heart Association. Circulation, 2021, 143, e1088-e1114.	1.6	30
194	Prognostic implications of procedural vs spontaneous myocardial infarction: Results from the Evaluation of Drug Eluting Stents and Ischemic Events (EVENT) registry. American Heart Journal, 2013, 166, 1027-1034.	1.2	29
195	Use and Effectiveness of Bivalirudin VersusÂUnfractionated Heparin for Percutaneous Coronary Intervention Among Patients With ST-Segment Elevation Myocardial Infarction in the United States. JACC: Cardiovascular Interventions, 2016, 9, 2376-2386.	1.1	29
196	Transient Ischemic Left Ventricular Cavity Dilation Is a Significant Predictor of Severe and Extensive Coronary Artery Disease and Adverse Outcome in Patients Undergoing Stress Echocardiography. Journal of the American Society of Echocardiography, 2007, 20, 352-358.	1.2	28
197	Angiotensin receptor blockers: baseline therapy in hypertension?. European Heart Journal, 2009, 30, 2427-2430.	1.0	28
198	Late Outcomes After Carotid Artery Stenting Versus Carotid Endarterectomy. Circulation, 2010, 122, 1091-1100.	1.6	28

#	Article	IF	Citations
199	Antihypertensive efficacy of angiotensin receptor blockers as monotherapy as evaluated by ambulatory blood pressure monitoring: a meta-analysis. European Heart Journal, 2014, 35, 1732-1742.	1.0	28
200	Trend in percutaneous coronary intervention volume following the COURAGE and BARI-2D trials. International Journal of Cardiology, 2015, 183, 6-10.	0.8	28
201	Rates of Invasive Management of Cardiogenic Shock in New York Before and After Exclusion From Public Reporting. JAMA Cardiology, 2016, 1, 640.	3.0	28
202	Long-Term Safety and Efficacy of Durable Polymer Cobalt-Chromium Everolimus-Eluting Stents in Patients at High Bleeding Risk. Circulation, 2020, 141, 891-901.	1.6	28
203	Optimal Treatment Strategies in Patients with Chronic Kidney Disease and Coronary Artery Disease. American Journal of Medicine, 2016, 129, 1288-1298.	0.6	27
204	Comparative Outcomes After Percutaneous Coronary Intervention Among Black and White Patients Treated at US Veterans Affairs Hospitals. JAMA Cardiology, 2017, 2, 967.	3.0	27
205	The presence, characterization and prognosis of coronary plaques among patients with zero coronary calcium scores. International Journal of Cardiovascular Imaging, 2011, 27, 805-812.	0.7	26
206	Percutaneous Coronary Intervention in Patients With Insulin-Treated and Nonâ€“Insulin-Treated Diabetes Mellitus. JAMA Cardiology, 2016, 1, 266.	3.0	26
207	Use of troponin assay 99th percentile as the decision level for myocardial infarction diagnosis. American Heart Journal, 2017, 190, 135-139.	1.2	26
208	Contrast media use in patients with chronic kidney disease undergoing coronary angiography: A systematic review and meta-analysis of randomized trials. International Journal of Cardiology, 2017, 228, 137-144.	0.8	26
209	Evidence-Based Practices in the Cardiac Catheterization Laboratory: A Scientific Statement From the American Heart Association. Circulation, 2021, 144, e107-e119.	1.6	26
210	Bleeding Risk Comparing Targeted Low-Dose Heparin With Bivalirudin in Patients Undergoing Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2011, 4, 463-473.	1.4	25
211	When Conventional Heart Failure Therapy is Not Enough: Angiotensin Receptor Blocker, Direct Renin Inhibitor, or Aldosterone Antagonist?. Congestive Heart Failure, 2013, 19, 107-115.	2.0	25
212	Secondary Prevention after Ischemic Stroke or Transient Ischemic Attack. American Journal of Medicine, 2014, 127, 728-738.	0.6	25
213	Effect of Previous Failure on Subsequent Procedural Outcomes of Chronic Total Occlusion Percutaneous Coronary Intervention (from a Contemporary Multicenter Registry). American Journal of Cardiology, 2016, 117, 1267-1271.	0.7	25
214	Management of hypertension in 2017. Current Opinion in Cardiology, 2017, 32, 413-421.	0.8	25
215	Meta-Analysis Comparing Patent Foramen Ovale Closure Versus Medical Therapy to Prevent Recurrent Cryptogenic Stroke. American Journal of Cardiology, 2018, 121, 649-655.	0.7	25
216	Nanoparticle eluting-angioplasty balloons to treat cardiovascular diseases. International Journal of Pharmaceutics, 2019, 554, 212-223.	2.6	25

#	Article	IF	Citations
217	Meta-Analysis of Prognostic Implications of Dyspnea Versus Chest Pain in Patients Referred for Stress Testing. American Journal of Cardiology, 2014, 113, 559-564.	0.7	24
218	Outcomes of Participants With Diabetes in the ISCHEMIA Trials. Circulation, 2021, 144, 1380-1395.	1.6	24
219	Which, if any, antihypertensive agents cause cancer?. Current Opinion in Cardiology, 2012, 27, 374-380.	0.8	23
220	Improving treatment adherence to antihypertensive therapy: the role of single-pill combinations. Expert Opinion on Pharmacotherapy, 2012, 13, 345-355.	0.9	23
221	Procedural variation in the performance of primary percutaneous coronary intervention for STâ€elevation myocardial infarction: A SCAIâ€based survey study of US interventional cardiologists. Catheterization and Cardiovascular Interventions, 2014, 83, 721-726.	0.7	23
222	Outcomes with Angiotensin-converting Enzyme Inhibitors vs Other Antihypertensive Agents in Hypertensive Blacks. American Journal of Medicine, 2015, 128, 1195-1203.	0.6	23
223	Stress testing in patients with chronic kidney disease: The need for ancillary markers for effective risk stratification and prognosis. Journal of Nuclear Cardiology, 2016, 23, 570-574.	1.4	23
224	Changing definition of hypertension in guidelines: how innocent a number game?. European Heart Journal, 2018, 39, 2241-2242.	1.0	23
225	Misconceptions and Facts About Beta-Blockers. American Journal of Medicine, 2019, 132, 816-819.	0.6	23
226	Risk of amputation associated with sodium-glucose co-transporter 2 inhibitors: A meta-analysis of five randomized controlled trials. Diabetes Research and Clinical Practice, 2020, 163, 108136.	1.1	23
227	Comparison of Heart Rate Reserve Versus 85% of Age-Predicted Maximum Heart Rate as a Measure of Chronotropic Response in Patients Undergoing Dobutamine Stress Echocardiography. American Journal of Cardiology, 2006, 97, 742-747.	0.7	22
228	Transient ST-segment episode detection for ECG beat classification. , 2011, , .		22
229	Coronary Intravascular Ultrasound. Circulation, 2013, 127, e868-74.	1.6	22
230	Predictors of Access Site Crossover in Patients Who Underwent Transradial Coronary Angiography. American Journal of Cardiology, 2015, 116, 379-383.	0.7	22
231	Evaluation of the efficacy and safety of dual antiplatelet therapy with or without warfarin in patients with a clinical indication for DAPT and chronic anticoagulation: A metaâ€analysis of observational studies. Catheterization and Cardiovascular Interventions, 2016, 88, E12-22.	0.7	22
232	Meta-Analysis of Culprit-Only Versus Multivessel Percutaneous Coronary Intervention in Patients With ST-Segment Elevation Myocardial Infarction and Multivessel Coronary Disease. American Journal of Cardiology, 2018, 121, 529-536.	0.7	22
233	Antihypertensive Efficacy of Aliskiren. Circulation, 2009, 119, 371-373.	1.6	21
234	Right Heart Catheterization, Coronary Angiography, and Percutaneous Coronary Intervention. Circulation, 2011, 124, e428-33.	1.6	21

#	Article	IF	Citations
235	A randomized comparison of modified subcutaneous â€œZâ€â€stitch versus manual compression to achieve hemostasis after large caliber femoral venous sheath removal. Catheterization and Cardiovascular Interventions, 2018, 91, 105-112.	0.7	21
236	Antithrombotic strategies after transcatheter aortic valve implantation: Insights from a network metaâ€analysis. Catheterization and Cardiovascular Interventions, 2020, 96, E177-E186.	0.7	21
237	Percutaneous coronary intervention or coronary artery bypass graft surgery for left main coronary artery disease: A meta-analysis of randomized trials. American Heart Journal, 2020, 227, 9-10.	1.2	21
238	Design and rationale of the XIENCE short DAPT clinical program: An assessment of the safety of 3-month and 1-month DAPT in patients at high bleeding risk undergoing PCI with an everolimus-eluting stent. American Heart Journal, 2021, 231, 147-156.	1.2	21
239	Comparison of Outcomes of Patients With Sepsis With Versus Without Acute Myocardial Infarction and Comparison of Invasive Versus Noninvasive Management of the Patients With Infarction. American Journal of Cardiology, 2016, 117, 1065-1071.	0.7	20
240	The Blood Pressure Landscape. Journal of the American College of Cardiology, 2018, 72, 1313-1316.	1.2	20
241	Nanoparticles for Detection and Treatment of Peripheral Arterial Disease. Small, 2018, 14, e1800644.	5.2	20
242	Atherectomy in belowâ€theâ€knee endovascular interventions: Oneâ€year outcomes from the XLPAD registry. Catheterization and Cardiovascular Interventions, 2019, 93, 488-493.	0.7	20
243	Nonculprit Lesion Severity and Outcome of Revascularization in Patients With STEMI and Multivessel Coronary Disease. Journal of the American College of Cardiology, 2020, 76, 1277-1286.	1.2	20
244	Trials on the Effect of Cardiac Resynchronization on Arterial Blood Pressure in Patients With Heart Failure. American Journal of Cardiology, 2011, 107, 561-568.	0.7	19
245	Comparative Assessment of Procedure Cost and Outcomes Between Guidewire and Crossing Device Strategies to Cross Peripheral Artery Chronic Total Occlusions. JACC: Cardiovascular Interventions, 2016, 9, 2243-2252.	1.1	19
246	In-Hospital Mortality and Major Adverse Cardiovascular Events after Kidney Transplantation in the United States. CardioRenal Medicine, 2019, 9, 51-60.	0.7	19
247	Incremental Prognostic Value of Stress Echocardiography Over Clinical and Stress Electrocardiographic Variables in Patients With Prior Myocardial Infarction: "Warranty Time" of a Normal Stress Echocardiogram. Echocardiography, 2006, 23, 455-464.	0.3	18
248	A Routine Invasive Strategy for Out-of-Hospital Cardiac Arrest Survivors. Circulation: Cardiovascular Interventions, 2010, 3, 197-199.	1.4	18
249	Inotropic Contractile Reserve Can Risk-Stratify Patients With HIV Cardiomyopathy. JACC: Cardiovascular Imaging, 2011, 4, 1231-1238.	2.3	18
250	The Effect of Statin Therapy on Ventricular Tachyarrhythmias: A Meta-Analysis. American Journal of Therapeutics, 2012, 19, 16-23.	0.5	18
251	Temporal trends in clinical characteristics of patients without known cardiovascular disease with a first episode of myocardial infarction. American Heart Journal, 2014, 167, 480-488.e1.	1.2	18
252	Association between low ankle-brachial index and accelerometer-derived sedentary and exercise time in the asymptomatic general population. Vascular Medicine, 2015, 20, 332-338.	0.8	18

#	Article	IF	Citations
253	Outcomes with bioabsorbable vascular scaffolds versus everolimus eluting stents. International Journal of Cardiology, 2016, 212, 214-222.	0.8	18
254	Differences in Whole Blood Platelet Aggregation at Baseline and in Response to Aspirin and Aspirin Plus Clopidogrel in Patients With Versus Without Chronic Kidney Disease. American Journal of Cardiology, 2016, 117, 656-663.	0.7	18
255	Meta-analysis of Antithrombotic Therapy in Patients With Atrial Fibrillation Undergoing Percutaneous Coronary Intervention. American Journal of Cardiology, 2020, 125, 521-527.	0.7	18
256	P2Y12 inhibitor versus aspirin monotherapy for secondary prevention of cardiovascular events: meta-analysis of randomized trials. European Heart Journal Open, 2022, 2, .	0.9	18
257	Non-ST-Elevation Myocardial Infarction Patients Who Present During Off Hours Have Higher Risk Profiles and are Treated Less Aggressively, but Their Outcomes are Not Worse. Critical Pathways in Cardiology, 2009, 8, 29-33.	0.2	17
258	Endothelial progenitor cell response to antiproliferative drug exposure. Atherosclerosis, 2012, 225, 91-98.	0.4	17
259	Comparison of Lower Extremity Endovascular Intervention Outcomes in Women Versus Men. American Journal of Cardiology, 2017, 119, 490-496.	0.7	17
260	Comparative assessment of patient outcomes with intraluminal or subintimal crossing of infrainguinal peripheral artery chronic total occlusions. Vascular Medicine, 2018, 23, 39-45.	0.8	17
261	Identification of gene expression profiles in myocardial infarction: a systematic review and meta-analysis. BMC Medical Genomics, 2018, 11, 109.	0.7	17
262	Atorvastatin Has a Doseâ€Dependent Beneficial Effect on Kidney Function and Associated Cardiovascular Outcomes: Post Hoc Analysis of 6 Doubleâ€Blind Randomized Controlled Trials. Journal of the American Heart Association, 2019, 8, e010827.	1.6	17
263	Meta-Analysis Comparing WatchmanTM and Amplatzer Devices for Stroke Prevention in Atrial Fibrillation. Frontiers in Cardiovascular Medicine, 2020, 7, 89.	1.1	17
264	A Novel Pathway for the Management of Hypertension for Hospitalized Patients. Critical Pathways in Cardiology, 2007, 6, 150-160.	0.2	16
265	Risk Stratification and Prognosis in Octogenarians Undergoing Stress Echocardiographic Study. Echocardiography, 2007, 24, 851-859.	0.3	16
266	Usefulness of Stress Echocardiography for Risk Stratification and Prognosis of Patients With Left Ventricular Hypertrophy. American Journal of Cardiology, 2007, 100, 536-543.	0.7	16
267	Cardiovascular drugs and cancer: of competing risk, smallpox, Bernoulli, and d'Alembert. European Heart Journal, 2013, 34, 1095-1098.	1.0	16
268	The Prognostic Impact of High On-Treatment Platelet Reactivity with Aspirin or ADP Receptor Antagonists: Systematic Review and Meta-Analysis. BioMed Research International, 2014, 2014, 1-13.	0.9	16
269	A prospective study of arm circumference and risk of death in Bangladesh. International Journal of Epidemiology, 2014, 43, 1187-1196.	0.9	16
270	Saphenous Vein Graft Interventions. Current Treatment Options in Cardiovascular Medicine, 2014, 16, 301.	0.4	16

#	Article	IF	Citations
271	PCSK9 Inhibitors for Statin Intolerance?. JAMA - Journal of the American Medical Association, 2016, 315, 1571.	3.8	16
272	Age, Blood Pressure Targets, and Guidelines. Circulation, 2018, 138, 128-130.	1.6	16
273	Outcomes with cilostazol after endovascular therapy of peripheral artery disease. Vascular Medicine, 2019, 24, 313-323.	0.8	16
274	Ivabradine in Cardiovascular Disease Management Revisited: a Review. Cardiovascular Drugs and Therapy, 2021, 35, 1045-1056.	1.3	16
275	Standardizing the Definition and Analysis Methodology for Complete Coronary Artery Revascularization. Journal of the American Heart Association, 2021, 10, e020110.	1.6	16
276	Bridging Antiplatelet Therapy After Percutaneous Coronary Intervention. Journal of the American College of Cardiology, 2021, 78, 1550-1563.	1.2	16
277	Inotropic Contractile Reserve and Response to Cardiac Resynchronization Therapy in Patients with Markedly Remodeled Left Ventricle. Journal of the American Society of Echocardiography, 2011, 24, 91-97.	1.2	15
278	The Resoluteâ„¢ Integrity Zotarolimus-Eluting Stent in Coronary Artery Disease: A Review. Cardiology and Therapy, 2013, 2, 17-25.	1.1	15
279	ALTITUDE Trial and Dual RAS Blockade: The Alluring but Soft Science of the Surrogate End Point. American Journal of Medicine, 2013, 126, e1-e3.	0.6	15
280	Practice Patterns and In-Hospital Outcomes Associated With Bivalirudin Use Among Patients With Nonâ€“ST-Segmentâ€“Elevation Myocardial Infarction Undergoing Percutaneous Coronary Intervention in the United States. Circulation: Cardiovascular Quality and Outcomes, 2017, 10, .	0.9	15
281	Body-Weight Fluctuations and Outcomes in Coronary Disease. New England Journal of Medicine, 2017, 377, 94-96.	13.9	15
282	Perioperative cardiovascular outcomes of non-cardiac solid organ transplant surgery. European Heart Journal Quality of Care & Clinical Outcomes, 2019, 5, 72-78.	1.8	15
283	Comparative Outcomes of Supera Interwoven Nitinol vs Bare Nitinol Stents for the Treatment of Femoropopliteal Disease: Insights From the XLPAD Registry. Journal of Endovascular Therapy, 2020, 27, 60-65.	0.8	15
284	Safety and efficacy of mechanical circulatory support with Impella or intraâ€aortic balloon pump for highâ€risk percutaneous coronary intervention and/or cardiogenic shock: Insights from a network metaâ€analysis of randomized trials. Catheterization and Cardiovascular Interventions, 2021, 97, E636-E645.	0.7	15
285	Ambulatory Blood Pressure Monitoring to Predict Response to Renal Denervation. Hypertension, 2021, 77, 529-536.	1.3	15
286	Causes of cardiovascular and noncardiovascular death in the ISCHEMIA trial. American Heart Journal, 2022, 248, 72-83.	1.2	15
287	Influence of Human Immunodeficiency Virus Seropositive Status on the In-Hospital Management and Outcomes of Patients Presenting With Acute Myocardial Infarction. Journal of Invasive Cardiology, 2016, 28, 403-409.	0.4	15
288	Of Statistical Significance: â€œTrendsâ€•Toward Significance and Optimism Bias. Journal of the American College of Cardiology, 2006, 48, 1471.	1.2	14

#	Article	IF	Citations
289	Prognostic Value of Stress Echocardiogram in Patients With Angiographically Significant Coronary Artery Disease. American Journal of Cardiology, 2012, 109, 153-158.	0.7	14
290	Impaired Myocardial Oxygenation Response to Stress in Patients With Chronic Kidney Disease. Journal of the American Heart Association, 2015, 4, e002249.	1.6	14
291	Evidence-Based Management of Stable Ischemic Heart Disease. JAMA - Journal of the American Medical Association, 2015, 314, 1917.	3.8	14
292	Duration of Dual Antiplatelet Therapy in Patients with an Acute Coronary Syndrome Undergoing Percutaneous Coronary Intervention. American Journal of Medicine, 2017, 130, 1325.e1-1325.e12.	0.6	14
293	The Burden of Atherosclerotic Cardiovascular Disease in South Asians Residing in Canada: A Reflection From the South Asian Heart Alliance. CJC Open, 2019, 1, 271-281.	0.7	14
294	Intravenous Antiplatelet Therapy Bridging in Patients Undergoing Cardiac or Non-Cardiac Surgery Following Percutaneous Coronary Intervention. Cardiovascular Revascularization Medicine, 2019, 20, 805-811.	0.3	14
295	The Elusive Late Benefit of Biodegradable Polymer Drug-Eluting Stents. Circulation, 2019, 139, 334-336.	1.6	14
296	Outcomes With Complete Versus Incomplete Revascularization in Patients With Multivessel Coronary Disease Undergoing Percutaneous Coronary Intervention With Everolimus Eluting Stents. American Journal of Cardiology, 2020, 125, 362-369.	0.7	14
297	Association of Blood Pressure Variability and Diuretics With Cardiovascular Events in Patients With Chronic Kidney Disease Stages 1â€“5. Hypertension, 2021, 77, 948-959.	1.3	14
298	Impact of Hospital Procedural Volume onÂOutcomes After Endovascular Revascularization for Critical LimbÂIschemia. JACC: Cardiovascular Interventions, 2021, 14, 1926-1936.	1.1	14
299	Randomised comparison of a biodegradable polymer ultra-thin sirolimus-eluting stent versus a durable polymer everolimus-eluting stent in patients with de novo native coronary artery lesions: the meriT-V trial. EuroIntervention, 2018, 14, e1207-e1214.	1.4	14
300	Predictors of Left Main Coronary Artery Disease in the ISCHEMIA Trial. Journal of the American College of Cardiology, 2022, 79, 651-661.	1.2	14
301	â€œOneâ€•Cup of Coffee and Nuclear SPECT to Go. Journal of the American College of Cardiology, 2007, 49, 528.	1.2	13
302	Efficacy and Safety of Dual Calcium Channel Blockade for the Treatment of Hypertension: A Meta-Analysis. American Journal of Hypertension, 2013, 26, 287-297.	1.0	13
303	Heparin Monotherapy or Bivalirudin During Percutaneous Coronary Intervention in Patients With Nonâ€“ST-Segmentâ€“Elevation Acute Coronary Syndromes or Stable Ischemic Heart Disease. Circulation: Cardiovascular Interventions, 2014, 7, 365-373.	1.4	13
304	Should We SPRINT Toward New Blood Pressure Goals or Let the Dust Settle?. American Journal of Medicine, 2016, 129, 769-770.	0.6	13
305	Treatment-Resistant Hypertension and Outcomes Based on Randomized Treatment Group in ALLHAT. American Journal of Medicine, 2017, 130, 439-448.e9.	0.6	13
306	Trends in Perioperative Venous Thromboembolism Associated with Major Noncardiac Surgery. TH Open, 2017, 01, e82-e91.	0.7	13

#	Article	IF	Citations
307	The Potential Effects of New Stent Platforms for Coronary Revascularization in Patients With Diabetes. Canadian Journal of Cardiology, 2018, 34, 653-664.	0.8	13
308	Effects of initial invasive vs. initial conservative treatment strategies on recurrent and total cardiovascular events in the ISCHEMIA trial. European Heart Journal, 2022, 43, 148-149.	1.0	13
309	Treatment-resistant hypertension: another Cinderella story. European Heart Journal, 2013, 34, 1175-1177.	1.0	12
310	Surrogate and clinical outcomes following ischemic postconditioning during primary percutaneous coronary intervention of STâ€Segment elevation myocardial infarction: A metaâ€analysis of 15 randomized trials. Catheterization and Cardiovascular Interventions, 2014, 84, 978-986.	0.7	12
311	Significance of an Abnormal Ankle-Brachial Index in Patients With Established Coronary Artery Disease With and Without Associated Diabetes Mellitus. American Journal of Cardiology, 2014, 113, 1280-1284.	0.7	12
312	Lipid lowering in patients with treatment-resistant hypertension: an analysis from the Treating to New Targets (TNT) trial. European Heart Journal, 2014, 35, 1801-1808.	1.0	12
313	Mechanical Interaction of an Expanding Coiled Stent with a Plaque-Containing Arterial Wall: A Finite Element Analysis. Cardiovascular Engineering and Technology, 2016, 7, 58-68.	0.7	12
314	Hypertension control and cardiovascular disease. Lancet, The, 2017, 389, 153.	6.3	12
315	Do We Need a Trial of DES Versus CABG Surgery in Diabetic Patients With ACS?. Journal of the American College of Cardiology, 2017, 70, 3007-3009.	1.2	12
316	Coronary atherectomy is associated with improved procedural and clinical outcomes among patients with calcified coronary lesions: Insights from the VA CART program. Catheterization and Cardiovascular Interventions, 2018, 91, 1009-1017.	0.7	12
317	Drug-coated balloon in peripheral artery disease. Cardiovascular Revascularization Medicine, 2019, 20, 338-343.	0.3	12
318	Sexâ€Related Differences in Patients at High Bleeding Risk Undergoing Percutaneous Coronary Intervention: A Patientâ€Level Pooled Analysis From 4 Postapproval Studies. Journal of the American Heart Association, 2020, 9, e014611.	1.6	12
319	Contemporary Revascularization Strategies and Outcomes Among Patients With Diabetes With Critical Limb Ischemia. JACC: Cardiovascular Interventions, 2021, 14, 664-674.	1.1	12
320	Cardiogenic shock complicating multisystem inflammatory syndrome following COVID-19 infection: a case report. BMC Cardiovascular Disorders, 2021, 21, 522.	0.7	12
321	Stress Function Index, a Novel Index for Risk Stratification and Prognosis Using Stress Echocardiography. Journal of the American Society of Echocardiography, 2005, 18, 1335-1342.	1.2	11
322	Risk Stratification and Prognosis of Human Immunodeficiency Virusâ€"Infected Patients With Known or Suspected Coronary Artery Disease Referred for Stress Echocardiography. Circulation: Cardiovascular Imaging, 2011, 4, 363-370.	1.3	11
323	Triple versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Adding Cilostazol to Aspirin and Clopidogrel?. Cardiology, 2013, 126, 233-243.	0.6	11
324	Longâ€term efficacy and safety of zotarolimusâ€eluting stent in patients with diabetes mellitus: Pooled 5â€year results from the ENDEAVOR III and IV trials. Catheterization and Cardiovascular Interventions, 2013, 82, 1031-1038.	0.7	11

#	Article	IF	Citations
325	From Doorâ€¢toâ€Balloon Time to Contactâ€¢toâ€Device Time: Predictors of Achieving Target Times in Patients With <scp>ST</scp>â€Elevation Myocardial Infarction. Clinical Cardiology, 2014, 37, 389-394.	0.7	11
326	Effectiveness of Fluorography Versus Cineangiography at Reducing Radiation Exposure During Diagnostic Coronary Angiography. American Journal of Cardiology, 2014, 113, 1093-1098.	0.7	11
327	Antihypertensive Therapy and the J-curve: Fact or Fiction?. Current Hypertension Reports, 2015, 17, 6.	1.5	11
328	Ezetimibe Plus Moderate-dose Simvastatin After Acute Coronary Syndrome: What Are We IMPROVEing On?. American Journal of Medicine, 2015, 128, 914.e1-914.e4.	0.6	11
329	Meta-Analysis of Randomized Trials on the Efficacy and Safety of Angiotensin-Converting Enzyme Inhibitors in Patients â‰¥65ÂYears of Age. American Journal of Cardiology, 2016, 118, 1427-1436.	0.7	11
330	Rate of Secondary Intervention After Open Versus Endovascular Abdominal Aortic Aneurysm Repair. Journal of Surgical Research, 2018, 232, 99-106.	0.8	11
331	Cardiovascular hazards of insufficient treatment of depression among patients with known cardiovascular disease: a propensity score adjusted analysis. European Heart Journal Quality of Care & Clinical Outcomes, 2018, 4, 258-266.	1.8	11
332	Safety and efficacy of radial versus femoral access for rotational Atherectomy: A systematic review and meta-analysis. Cardiovascular Revascularization Medicine, 2019, 20, 241-247.	0.3	11
333	P2Y12 inhibitor monotherapy versus aspirin monotherapy after short-term dual antiplatelet therapy for percutaneous coronary intervention: Insights from a network meta-analysis of randomized trials. American Heart Journal, 2020, 227, 82-90.	1.2	11
334	Why Fibrinolytic Therapy for ST-Segmentâ€“Elevation Myocardial Infarction in the COVID-19 Pandemic Is Not Your New Best Friend. Circulation: Cardiovascular Quality and Outcomes, 2020, 13, e006885.	0.9	11
335	Concepts and Controversies: Lipid Management in Patients with Chronic Kidney Disease. Cardiovascular Drugs and Therapy, 2021, 35, 479-489.	1.3	11
336	Potent P2Y12 inhibitors versus Clopidogrel in elderly patients with acute coronary syndrome: Systematic review and meta-analysis. American Heart Journal, 2021, 237, 34-44.	1.2	11
337	Cardiovascular Risk Factors: It's Time to Focus on Variability!. Journal of Lipid and Atherosclerosis, 2020, 9, 255.	1.1	11
338	Drug-Eluting vs Bare-Metal Stents in Patients With Chronic Kidney Disease and Coronary Artery Disease: Insights From a Systematic Review and Meta-Analysis. Journal of Invasive Cardiology, 2018, 30, 10-17.	0.4	11
339	Comprehensive Quality-of-Life Outcomes With Invasive Versus Conservative Management of Chronic Coronary Disease in ISCHEMIA. Circulation, 2022, 145, 1294-1307.	1.6	11
340	Coronary Intervention in Patients With Acute Coronary Syndrome: Does Every Culprit Lesion Require Revascularization?. Current Cardiology Reports, 2010, 12, 330-337.	1.3	10
341	Amiodarone-induced Acute Respiratory Distress Syndrome Masquerading as Acute Heart Failure. Journal of Emergency Medicine, 2012, 43, e311-e314.	0.3	10
342	Prognostic Value of Myocardial Ischemic Electrocardiographic Response in Patients With Normal Stress Echocardiographic Study. American Journal of Cardiology, 2014, 113, 945-949.	0.7	10

#	Article	IF	Citations
343	A Case of Cardiogenic Shock Secondary to Complement-Mediated Myopericarditis From InfluenzaÂBÂInfection. Canadian Journal of Cardiology, 2017, 33, 1335.e1-1335.e3.	0.8	10
344	Chelation Therapy as a Cardiovascular Therapeutic Strategy: the Rationale and the Data in Review. Cardiovascular Drugs and Therapy, 2017, 31, 619-625.	1.3	10
345	ISCHEMIA: Establishing the Primary End Point. Circulation: Cardiovascular Quality and Outcomes, 2018, 11, e004791.	0.9	10
346	Blood Pressure Variability and Arterial Stiffnessâ€"Chicken or Egg?. JAMA Cardiology, 2019, 4, 1050.	3.0	10
347	Stable coronary artery disease. Journal of Hypertension, 2019, 37, 1112-1118.	0.3	10
348	Beta-blockers after acute myocardial infarction: an old drug in urgent need of new evidence!. European Heart Journal, 2020, 41, 3530-3532.	1.0	10
349	Duration of Antiplatelet Therapy Following Transcatheter Aortic Valve Replacement: Systematic Review and Network Metaâ€Analysis. Journal of the American Heart Association, 2021, 10, e019490.	1.6	10
350	Comparison of Days Alive Out of Hospital With Initial Invasive vs Conservative Management. JAMA Cardiology, 2021, 6, 1023.	3.0	10
351	Accelerated and intensified calcific atherosclerosis and microvascular dysfunction in patients with chronic kidney disease. Reviews in Cardiovascular Medicine, 2020, 21, 157.	0.5	10
352	Resting Heart Rate and Cardiovascular Disease: The Beta-Blockerâ€"Hypertension Paradox. Journal of the American College of Cardiology, 2008, 51, 330-331.	1.2	9
353	Blood pressure paradox in patients with nonâ€"ST-segment elevation acute coronary syndromes. American Heart Journal, 2009, 157, 525-531.	1.2	9
354	Prediction of Myocardial Infarction Versus Cardiac Death by Stress Echocardiography. Journal of the American Society of Echocardiography, 2009, 22, 261-267.	1.2	9
355	A prospective study of variability in systolic blood pressure and mortality in a rural Bangladeshi population cohort. Preventive Medicine, 2013, 57, 807-812.	1.6	9
356	Drugâ€eluting stents versus bare metal stents prior to noncardiac surgery. Catheterization and Cardiovascular Interventions, 2015, 85, 533-541.	0.7	9
357	Comparison of Dual-Antiplatelet Therapy Durations after Endovascular Revascularization of Infrainguinal Arteries. Annals of Vascular Surgery, 2015, 29, 1235-1244.	0.4	9
358	Applicability of the COURAGE, BARIÂ2D,Âand FREEDOM Trials to Contemporary Practice. Journal of the American College of Cardiology, 2016, 68, 996-998.	1.2	9
359	First-Generation Bioresorbable VascularÂScaffolds. Journal of the American College of Cardiology, 2017, 69, 3067-3069.	1.2	9
360	Predictors and Outcomes of StagedÂVersus One-Time MultivesselÂRevascularization in MultivesselÂCoronaryÂArtery Disease. JACC: Cardiovascular Interventions, 2018, 11, 2265-2273.	1.1	9

#	Article	IF	Citations
361	The muddy waters of the J-curve and coronary revascularization. European Heart Journal, 2020, 41, 1684-1686.	1.0	9
362	Why Are We Still Prescribing Angiotensin-Converting Enzyme Inhibitors?. Circulation, 2022, 145, 413-415.	1.6	9
363	International percutaneous coronary intervention complication survey. Catheterization and Cardiovascular Interventions, 2022, 99, 1733-1740.	0.7	9
364	When Guidelines Need Guidanceâ€¦. American Journal of Medicine, 2008, 121, 742-743.	0.6	8
365	Use of the Proxis embolic protection device for guide anchoring and stent delivery during complex saphenous vein graft interventions. Cardiovascular Revascularization Medicine, 2009, 10, 183-187.	0.3	8
366	Validation of Long-Term Benefits of Bivalirudin Versus Unfractionated Heparin in Routine Clinical Practice After Percutaneous Coronary Intervention. American Journal of Cardiology, 2010, 106, 1234-1240.	0.7	8
367	Response to Letter Regarding Article, â€œShort- and Long-Term Outcomes With Drug-Eluting and Bare-Metal Coronary Stents: A Mixed-Treatment Comparison Analysis of 117 762 Patient-years of Follow-up From Randomized Trialsâ€• Circulation, 2013, 127, e447.	1.6	8
368	Optimal aspirin dose in acute coronary syndromes: an emerging consensus. Future Cardiology, 2014, 10, 291-300.	0.5	8
369	Letter by Messerli et al Regarding Article, â€œThe Implications of Blood Pressure Measurement Methods on Treatment Targets for Blood Pressureâ€• Circulation, 2017, 135, e45-e46.	1.6	8
370	Lowering the Thresholds of Diseases. Journal of the American College of Cardiology, 2018, 71, 119-121.	1.2	8
371	Effect of Arteriovenous Fistula Creation on Systolic and Diastolic Blood Pressure in Patients With Pre-dialysis Advanced Chronic Kidney Disease. American Journal of Hypertension, 2019, 32, 858-867.	1.0	8
372	Outcome of Transcatheter Aortic Valve Implantation in Patients with Peripheral Vascular Disease. American Journal of Cardiology, 2019, 124, 416-422.	0.7	8
373	Optimal Duration of Dual Antiplatelet Therapy After Percutaneous Coronary Intervention in Patients With Acute Coronary Syndrome: Insights From a Network Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine, 2021, 28, 50-56.	0.3	8
374	Systematic Reviews and Meta-Analyses in Cardiac Surgery: Rules of the Road â€“ Part 1. Annals of Thoracic Surgery, 2021, 111, 754-761.	0.7	8
375	Tricuspid valve vegetation debulking using the <scp>AngioVac</scp> system. Catheterization and Cardiovascular Interventions, 2021, 98, E475-E477.	0.7	8
376	Cardioversion in Patients with Left Ventricular Thrombus Is Not Associated with Increased Thromboembolic Risk. Journal of the American Society of Echocardiography, 2006, 19, 438-440.	1.2	7
377	The Pickering Syndrome â€“ A pebble in the mosaic of the cardiorenal syndrome. Blood Pressure, 2011, 20, 1-2.	0.7	7
378	Plaque regression and progenitor cell mobilization with intensive lipid elimination regimen (PREMIER) trial design. Journal of Clinical Apheresis, 2014, 29, 97-106.	0.7	7

#	Article	IF	Citations
379	The role of antiplatelet therapy in patients with peripheral artery disease and lower extremity peripheral artery revascularization. Current Opinion in Cardiology, 2015, 30, 525-535.	0.8	7
380	Introduction: Controversies in Hypertension. Progress in Cardiovascular Diseases, 2016, 59, 207-208.	1.6	7
381	Accuracy of remote chest X-ray interpretation using Google Glass technology. International Journal of Cardiology, 2016, 219, 38-40.	0.8	7
382	Diagnostic, Therapeutic, and Clinical Trial Conundrum of Patients With Chronic Kidney Disease. JACC: Cardiovascular Interventions, 2016, 9, 2110-2112.	1.1	7
383	Rapid and Affordable 3-Dimensional Prototyping for Left Atrial Appendage Closure Planning. Circulation: Cardiovascular Interventions, 2017, 10, e004710.	1.4	7
384	Perioperative bleeding and thrombotic risks in patients with Von Willebrand disease. Journal of Thrombosis and Thrombolysis, 2017, 44, 67-70.	1.0	7
385	Blood pressure control and mortality in <scp>US</scp>â€•and foreignâ€born blacks in New York City. Journal of Clinical Hypertension, 2017, 19, 956-964.	1.0	7
386	Cholesterol variability: a marker for increased risk or a risk factor?. European Heart Journal, 2017, 38, 3567-3568.	1.0	7
387	Cardiovascular Disease and Gout: Real-World Experience Evaluating Patient Characteristics, Treatment Patterns, and Health Care Utilization. Journal of Managed Care & Specialty Pharmacy, 2017, 23, 677-683.	0.5	7
388	Economic burden associated with inadequate antidepressant medication management among patients with depression and known cardiovascular diseases: insights from a United Statesâ€“based retrospective claims database analysis. Journal of Medical Economics, 2020, 23, 262-270.	1.0	7
389	Fibrinolytic Strategy for ST-Segmentâ€“Elevation Myocardial Infarction. Circulation: Cardiovascular Interventions, 2020, 13, e009622.	1.4	7
390	Procedural Volume and Outcomes After Primary Percutaneous Coronary Intervention for STâ€Segmentâ€“Elevation Myocardial Infarction in Kerala, India: Report of the Cardiological Society of Indiaâ€“Kerala Primary Percutaneous Coronary Intervention Registry. Journal of the American Heart Association, 2020, 9, e014968.	1.6	7
391	Systematic Reviews and Meta-Analyses in Cardiac Surgery: Rules of the Road â€“ Part 2. Annals of Thoracic Surgery, 2021, 111, 762-770.	0.7	7
392	In-Hospital Outcomes and Trends of Endovascular Intervention vs Surgical Revascularization in Octogenarians With Peripheral Artery Disease. American Journal of Cardiology, 2021, 145, 143-150.	0.7	7
393	Efficacy and safety of the nitinol clip-based vascular closure device (Starclose) for closure of common femoral arterial cannulation at or near the bifurcation: a propensity score-adjusted analysis. Journal of Invasive Cardiology, 2011, 23, 194-9.	0.4	7
394	Crossing of infrainguinal peripheral arterial chronic total occlusion with a blunt microdissection catheter. Journal of Invasive Cardiology, 2014, 26, 363-9.	0.4	7
395	Effect of Ramipril on the Incidence of Diabetes. New England Journal of Medicine, 2007, 356, 522-524.	13.9	6
396	Cross-sectional Imaging Identifies Flow-mediated Vasodilatation More Accurately Compared with Longitudinal Imaging. Journal of the American Society of Echocardiography, 2007, 20, 1380-1385.	1.2	6

#	Article	IF	Citations
397	Is There an Ischemic Threshold Beyond Which Percutaneous Coronary Intervention Is Beneficial in the Clinical Outcomes Utilizing Revascularization and Aggressive Drug Evaluation (COURAGE) Trial?. American Journal of Cardiology, 2007, 100, 1495.	0.7	6
398	Diuretic-based regimens for obese patients?. Lancet, The, 2013, 381, 512-513.	6.3	6
399	How and When to Decide on Revascularization in Stable Ischemic Heart Disease. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 79-92.	0.4	6
400	Heart Rate in Coronary Artery Disease: Should We Lower It?. Current Treatment Options in Cardiovascular Medicine, 2013, 15, 118-128.	0.4	6
401	Response to Letter Regarding Article, â€œOutcomes With Coronary Artery Bypass Graft Surgery Versus Percutaneous Coronary Intervention for Patients With Diabetes Mellitus: Can Newer Generation Drug-Eluting Stents Bridge the Gap?â€• Circulation: Cardiovascular Interventions, 2014, 7, 729-729.	1.4	6
402	Paclitaxel-eluting vs. bare metal stent implantation in saphenous vein graft lesions: Very long-term follow-up of the SOS (Stenting of Saphenous vein grafts) trial. International Journal of Cardiology, 2015, 186, 261-263.	0.8	6
403	Safety of Perflutren Ultrasound Contrast Agents: A Disproportionality Analysis of the US FAERS Database. Drug Safety, 2015, 38, 1127-1139.	1.4	6
404	The Reply. American Journal of Medicine, 2015, 128, e25.	0.6	6
405	Challenges with Evidence-Based Management of Stable Ischemic Heart Disease. Current Cardiology Reports, 2017, 19, 11.	1.3	6
406	Drug-Eluting Stents for Treatment of Peripheral Artery Disease. American Journal of Cardiovascular Drugs, 2018, 18, 175-180.	1.0	6
407	Biodegradable Polymers and Stents: the Next Generation?. Current Cardiovascular Risk Reports, 2019, 13, 1.	0.8	6
408	Culprit Vessel Only Versus Multivessel Percutaneous Coronary Intervention in Acute Myocardial Infarction with Cardiogenic Shock: A Systematic Review and Meta-Analysis. Cardiovascular Revascularization Medicine, 2019, 20, 956-964.	0.3	6
409	The Impact of Peripheral Artery Disease in Chronic Total Occlusion Percutaneous Coronary Intervention (Insights From PROGRESS-CTO Registry). Angiology, 2020, 71, 274-280.	0.8	6
410	JetStream Atherectomy for the Treatment of In-Stent Restenosis of the Femoropopliteal Segment: One-Year Results of the JET-ISR Study. Journal of Endovascular Therapy, 2021, 28, 107-116.	0.8	6
411	Comparison of SYNTAX score strata effects of percutaneous and surgical revascularization trials: A meta-analysis. Journal of Thoracic and Cardiovascular Surgery, 2023, 165, 1405-1413.e13.	0.4	6
412	Differences Between Patients With Intermittent Claudication and Critical Limb Ischemia Undergoing Endovascular Intervention: Insights From the Excellence in Peripheral Artery Disease Registry. Circulation: Cardiovascular Interventions, 2021, 14, e010635.	1.4	6
413	Stent and Non-Stent Based Outcomes of Infrainguinal Peripheral Artery Interventions From the Multicenter XLPAD Registry. Journal of Invasive Cardiology, 2015, 27, 14-8.	0.4	6
414	Dialysis Initiation in Patients With Chronic Coronary Disease and Advanced Chronic Kidney Disease in ISCHEMIAâ€CKD. Journal of the American Heart Association, 2022, 11, e022003.	1.6	6

#	Article	IF	Citations
415	Obesity and Mortality: A Poorly Understood Relationship. American Journal of Cardiology, 2007, 99, 876-877.	0.7	5
416	Î²-blockers: No longer an option for uncomplicated hypertension. Current Cardiology Reports, 2007, 9, 441-446.	1.3	5
417	Do angiotensin receptor blockers prevent myocardial infarctions as well as other initial therapies?. Current Opinion in Cardiology, 2012, 27, 381-385.	0.8	5
418	Statin Therapy for Secondary Prevention: Is There a Gender Difference? Test for Interaction in Meta-Analysis Revisited. American Journal of Cardiology, 2012, 110, 1553-1554.	0.7	5
419	Embolic Protection Devices. Circulation, 2014, 129, e470-6.	1.6	5
420	Retrograde approach to an ostial left anterior descending chronic total occlusion through a left internal mammary artery graft. Catheterization and Cardiovascular Interventions, 2016, 87, E224-8.	0.7	5
421	3-Year Results of a TAVR Trial in High Surgical Risk Patients. Journal of the American College of Cardiology, 2016, 67, 2575-2577.	1.2	5
422	Salt, Tomato Soup, and the Hypocrisy of the American Heart Association. American Journal of Medicine, 2017, 130, 392-393.	0.6	5
423	Trends in the Incidence and In-Hospital Outcomes of Cardiogenic Shock Complicating Thyroid Storm. American Journal of the Medical Sciences, 2017, 354, 159-164.	0.4	5
424	Reply. Journal of the American College of Cardiology, 2017, 70, 510.	1.2	5
425	Reply. Journal of the American College of Cardiology, 2017, 70, 120.	1.2	5
426	Does VALIDATE-SWEDEHEART invalidate the use of bivalirudin in myocardial infarction?. Journal of Thoracic Disease, 2018, 10, 70-74.	0.6	5
427	Detection of Atherosclerotic Cardiovascular Disease in Patients with Advanced Chronic Kidney Disease in the Cardiology and Nephrology Communities. CardioRenal Medicine, 2018, 8, 285-295.	0.7	5
428	Drug-Eluting Versus Bare Metal Stents in Saphenous Vein Graft Intervention: An Updated Comprehensive Meta-Analysis of Randomized Trials. Cardiovascular Revascularization Medicine, 2019, 20, 758-767.	0.3	5
429	Mortality in patients undergoing revascularization with paclitaxel eluting devices for infrainguinal peripheral artery disease: Insights from a network <scp>metaâ€analysis</scp> of randomized trials. Catheterization and Cardiovascular Interventions, 2020, 96, E467-E478.	0.7	5
430	Invasive Management of Coronary Artery Disease in Advanced Renal Disease. Kidney International Reports, 2021, 6, 1513-1524.	0.4	5
431	Impact of Chronic Kidney Disease on Revascularization and Outcomes in Patients with ST-Elevation Myocardial Infarction. American Journal of Cardiology, 2021, 150, 15-23.	0.7	5
432	Patterns of Use and Clinical Outcomes with Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers in Acute Heart Failure and Changes in Kidney Function: An Analysis of the Veteransâ€™ Health Administrative Database. CardioRenal Medicine, 2021, 11, 226-236.	0.7	5

#	Article	IF	Citations
433	Late loss in a disappearing frame of reference: is it still applicable to fully absorbable scaffolds?. EuroIntervention, 2009, 5, F43-F48.	1.4	5
434	Community acute kidney injury is associated with short- and long-term adverse outcomes inÂpatients admitted with acute myocardial infarction. Clinical Nephrology, 2018, 90, 404-412.	0.4	5
435	Telmisartan, ramipril, or both in patients at high risk of vascular events. New England Journal of Medicine, 2008, 359, 426-7; author reply 427.	13.9	5
436	Residual stroke risk after left atrial appendage closure in patients with prior oral anticoagulation failure. International Journal of Cardiology, 2022, 354, 17-21.	0.8	5
437	Invasive Versus Medical Management in Patients With Chronic Kidney Disease and Nonâ€“STâ€Segmentâ€“Elevation Myocardial Infarction. Journal of the American Heart Association, 2022, 11, .	1.6	5
438	Comparison of stress-induced myocardial ischemia in patients with and without coronary arterial collaterals. American Journal of Cardiology, 2004, 94, 1232-1236.	0.7	4
439	Beta-Blockers and Exercise. Journal of the American College of Cardiology, 2006, 48, 1284-1285.	1.2	4
440	Role of angiographic coronary artery collaterals in transient ischemic left ventricular cavity dilatation during stress echocardiography. Clinical Cardiology, 2006, 29, 305-310.	0.7	4
441	ISCHEMIA in chronic kidney disease: improving the representation of patients with chronic kidney disease in cardiovascular trials. Kidney International, 2016, 89, 1178-1179.	2.6	4
442	Who Should Undergo ChronicÂTotalÂOcclusion PercutaneousÂCoronaryÂIntervention?. Journal of the American College of Cardiology, 2016, 68, 1633-1636.	1.2	4
443	Preventive Strategies for Contrast-Induced Acute Kidney Injury. Circulation: Cardiovascular Interventions, 2017, 10, .	1.4	4
444	The Evolution of Myocardial Infarction: When the Truths We Hold To Be Self-Evident No Longer Have Evidence. Canadian Journal of Cardiology, 2017, 33, 1209-1211.	0.8	4
445	What Ever Happened to Cardioprotection With Î²-Blockers?. Mayo Clinic Proceedings, 2018, 93, 401-403.	1.4	4
446	Increasing inclusion of patients with advanced chronic kidney disease in cardiovascular clinical trials. Kidney International, 2018, 93, 787-788.	2.6	4
447	Current Trends and Future Perspectives in the Treatment of Pulmonary Arterial Hypertension. Current Problems in Cardiology, 2018, 43, 191-216.	1.1	4
448	Long-Term Outcomes of Drug-Eluting Stents Versus Bare-Metal Stents in End-Stage Renal Disease Patients on Dialysis. Cardiology in Review, 2018, 26, 277-286.	0.6	4
449	Prasugrel in the Elderly. Circulation, 2018, 137, 2446-2449.	1.6	4
450	Cardiovascular disease care fragmentation in kidney transplantation: a call for action. Kidney International, 2019, 96, 568-571.	2.6	4

#	Article	IF	Citations
451	Relation of Admission Blood Pressure to In-hospital and 90-Day Outcomes in Patients Presenting With Transient Ischemic Attack. American Journal of Cardiology, 2019, 123, 1083-1095.	0.7	4
452	Meta-Analysis Comparing Direct Oral Anticoagulants to Low Molecular Weight Heparin for Treatment of Venous Thromboembolism in Patients With Cancer. American Journal of Cardiology, 2020, 133, 175-178.	0.7	4
453	Acute coronary syndromes in the periâ€operative period after kidney transplantation in United States. Clinical Transplantation, 2020, 34, e14083.	0.8	4
454	Early Post-Percutaneous Coronary Intervention Chest Pain: A Nationwide Survey on Interventional Cardiologists' Perspective. Cardiovascular Revascularization Medicine, 2020, 21, 1517-1522.	0.3	4
455	Predictors of Outcome in the ISCHEMIA-CKD Trial: Anatomy versus Ischemia. American Heart Journal, 2021, 243, 187-200.	1.2	4
456	Perindopril vs Enalapril in Patients with Systolic Heart Failure: Systematic Review and Metaanalysis. Ochsner Journal, 2014, 14, 350-8.	0.5	4
457	Electronic alerts to initiate anticoagulation dialogue in patients with atrial fibrillation. American Heart Journal, 2022, 245, 29-40.	1.2	4
458	Safety and efficacy of drugâ€coated balloon for peripheral artery revascularizationâ€"A systematic review and metaâ€analysis. Catheterization and Cardiovascular Interventions, 2022, , .	0.7	4
459	Outcomes With Intermediate Left Main Disease: Analysis From the ISCHEMIA Trial. Circulation: Cardiovascular Interventions, 2022, 15, CIRCINTERVENTIONS121010925.	1.4	4
460	Endovascular Treatment and Outcomes for Femoropopliteal In-Stent Restenosis: Insights from the XLPAD Registry. Journal of Interventional Cardiology, 2022, 2022, 1-9.	0.5	4
461	Dobutamine stress echocardiography: Does it predict response to beta-blockers in patients with heart failure?. Current Heart Failure Reports, 2006, 3, 96-102.	1.3	3
462	Perioperative Î² blockade. Lancet, The, 2008, 372, 1147-1148.	6.3	3
463	Blood Pressure and Stroke. Journal of the American College of Cardiology, 2011, 57, 114-115.	1.2	3
464	Comparison of Coronary Artery Bypass Graft Surgery and Percutaneous Coronary Intervention in Patients with Diabetes. Current Treatment Options in Cardiovascular Medicine, 2015, 17, 377.	0.4	3
465	Update on Coronary Chronic Total Occlusion Percutaneous Coronary Intervention. Interventional Cardiology Clinics, 2016, 5, 177-186.	0.2	3
466	Drug-Coated Balloons. Interventional Cardiology Clinics, 2017, 6, 217-225.	0.2	3
467	Accuracy of 82Rb PET/CT Myocardial Perfusion Imaging with Regadenoson Stress, Including 3-Year Clinical Outcomes. Journal of Nuclear Medicine Technology, 2017, 45, 75-81.	0.4	3
468	Are ACE inhibitors acceptable ingredients in polypills?. Lancet, The, 2017, 390, 26.	6.3	3

#	Article	IF	Citations
469	Statins for Prevention of Contrast-Associated Acute Kidney Injury: Is the Debate a Moot Point?. Cardiovascular Revascularization Medicine, 2019, 20, 632-633.	0.3	3
470	Comparison of In-Hospital Outcomes in Patients Having Limb-Revascularization With Versus Without Atrial Fibrillation. American Journal of Cardiology, 2019, 124, 1540-1548.	0.7	3
471	Outcomes of Percutaneous Coronary Intervention and Coronary Artery Bypass Graft Surgery for Multivessel Coronary Artery Disease. JAMA Cardiology, 2019, 4, 507.	3.0	3
472	Everolimus Eluting Stents in Patients with Diabetes Mellitus and Chronic Kidney Disease: Insights from the TUXEDO Trial. Cardiovascular Revascularization Medicine, 2019, 20, 1075-1080.	0.3	3
473	Diverse perspectives and training paths in cardiology: An analysis of authorship in the Journal of the American College of Cardiology. Hellenic Journal of Cardiology, 2019, 60, 352-354.	0.4	3
474	Protected Rotational Atherectomy and DK NanoCrush POT rePOT Technique With Dual Guiding Catheters for Unprotected Distal Left Main. JACC: Cardiovascular Interventions, 2020, 13, e191-e193.	1.1	3
475	Comparative 12-Month Outcomes of Drug-Coated Balloon Versus Non-Drug-Coated Balloon Revascularization Strategy in Chronic Limb-Threatening Ischemia: Results From the XLPAD Registry. Cardiovascular Revascularization Medicine, 2020, 21, 1276-1284.	0.3	3
476	Coronary revascularization and circulatory support strategies in patients with myocardial infarction, multi-vessel coronary artery disease, and cardiogenic shock: Insights from an international survey. American Heart Journal, 2020, 225, 55-59.	1.2	3
477	Clinical outcomes of patients with and without chronic kidney disease undergoing endovascular revascularization of infrainguinal peripheral artery disease: Insights from the XLPAD registry. Catheterization and Cardiovascular Interventions, 2021, 98, 310-316.	0.7	3
478	Challenges of long-term dual antiplatelet therapy use following acute coronary syndromes. American Heart Journal, 2022, 246, 44-64.	1.2	3
479	How useful are beta-blockers in cardiovascular disease?. Anatolian Journal of Cardiology, 2006, 6, 358-63.	0.4	3
480	Optical coherence tomography-guided percutaneous coronary interventions. Journal of Invasive Cardiology, 2010, 22, 546-7.	0.4	3
481	Intravascular ultrasound-guided true lumen re-entry for successful recanalization of chronic total occlusions. Journal of Invasive Cardiology, 2010, 22, 608-10.	0.4	3
482	Prognostic value of computed tomography derived fractional flow reserve for predicting cardiac events and mortality in kidney transplant candidates. Journal of Cardiovascular Computed Tomography, 2022, 16, 442-451.	0.7	3
483	Translation of Critical Pathways for Acute Coronary Syndrome and for Acute Heart Failure Into Admission Forms and Discharge Planning. Critical Pathways in Cardiology, 2005, 4, 59-63.	0.2	2
484	Translation of the RACE Pathway for Management of Atrial Fibrillation and Atrial Flutter Into Admission Forms. Critical Pathways in Cardiology, 2006, 5, 15-17.	0.2	2
485	Valsartan Inefficacy or Ill-Effects of Concomitant Medications!. American Journal of Cardiology, 2010, 106, 602-603.	0.7	2
486	RELATIONSHIP OF HEART RATE AND CARDIOVASCULAR EVENTS IN PATIENTS AFTER ACUTE CORONARY SYNDROMES: AN ANALYSIS FROM THE PROVE-IT TIMI 22 TRIAL. Journal of the American College of Cardiology, 2010, 55, A98.E924.	1.2	2

#	Article	IF	Citations
487	Reninâ€“angiotensin system inhibitors and risk of cancer. Trends in Molecular Medicine, 2011, 17, 176-177.	3.5	2
488	J-Curve Phenomenon: Does It Exist?. , 2012, , 295-308.		2
489	Optimal reninâ€“angiotensin system blockadeâ€”wishful thinking?. Nature Reviews Cardiology, 2013, 10, 486-486.	6.1	2
490	Complete Revascularization in Contemporary Practice. Circulation: Cardiovascular Interventions, 2013, 6, 5-7.	1.4	2
491	Lipidâ€Lowering in African Americans in <scp>ALLHATâ€”</scp>Optimism Bias?. Journal of Clinical Hypertension, 2013, 15, 940-940.	1.0	2
492	Blood pressure lowering in patients with type 2 diabetes improves cardiovascular events including mortality, but more intensive lowering to systolic blood pressure less than 130â€…mmâ€…Hg is associated with further reduction in stroke and albuminuria without further reduction in cardiac events: TableÂ1. Evidence-Based Medicine, 2015, 20, 183-184.	0.6	2
493	Antianginal Agents for the Management of Stable Ischemic Heart Disease. Cardiology in Review, 2016, 24, 177-189.	0.6	2
494	Is the Use of Bare-Metal Stents Justifiable in the Era of Second-Generation Drug-Eluting Stents?. Canadian Journal of Cardiology, 2016, 32, 941.e7-941.e9.	0.8	2
495	Heart rate lowering by beta-blockade and cardiovascular events. Journal of Hypertension, 2016, 34, 2102-2103.	0.3	2
496	Ivabradine in Coronary Heart Diseaseâ€”The Emperor Has No Clothes. American Journal of Cardiology, 2017, 120, e15.	0.7	2
497	Full Metal Jacket. JACC: Cardiovascular Interventions, 2017, 10, 1413-1414.	1.1	2
498	PCI or CABG for severe unprotected left main coronary artery disease: making sense of the NOBLE and EXCEL trials. Journal of Thoracic Disease, 2017, 9, E451-E456.	0.6	2
499	Transcatheter closure of the left atrial appendage: A focused update on the Watchman closure device. Catheterization and Cardiovascular Interventions, 2018, 92, E28-E34.	0.7	2
500	Drug-Coated Balloon for Long Femoropopliteal Lesions. Circulation: Cardiovascular Interventions, 2018, 11, e007084.	1.4	2
501	The â€œFragilityâ€•of Mortality Benefit ofÂCoronary Artery Bypass Graft SurgeryÂin Diabetics. Journal of the American College of Cardiology, 2019, 73, 639-642.	1.2	2
502	Comparative influence of bleeding and ischemic risk factors on diabetic patients undergoing percutaneous coronary intervention with everolimusâ€eluting stents. Catheterization and Cardiovascular Interventions, 2021, 98, 1111-1119.	0.7	2
503	Biomarkers to Personalize Preoperative Cardiovascular Risk Stratification: Ready for Prime Time?. Annals of Internal Medicine, 2020, 172, 149.	2.0	2
504	Beta-Blocker Therapy After Myocardial Infarction: Is There an Expiry Date?. Canadian Journal of Cardiology, 2020, 36, 1577-1579.	0.8	2

#	Article	IF	Citations
505	Impact of renal function in high bleeding risk patients undergoing percutaneous coronary intervention: a patient-level stratified analysis from four post-approval studies. Journal of Thrombosis and Thrombolysis, 2021, 52, 419-428.	1.0	2
506	<scp>Inâ€hospital</scp> outcomes of endovascular versus surgical revascularization for chronic total occlusion in peripheral artery disease. Catheterization and Cardiovascular Interventions, 2021, 98, E586-E593.	0.7	2
507	OUP accepted manuscript. European Heart Journal, 2021, , .	1.0	2
508	Putting the 2021 ACC/AHA/SCAI Guideline for Coronary Artery Revascularization Into Practice. JACC: Case Reports, 2022, 4, 31-35.	0.3	2
509	Implementation of supervised exercise therapy in a veteran population with symptomatic claudication. Vascular Medicine, 2022, 27, 136-141.	0.8	2
510	Crush techniques for percutaneous coronary intervention of bifurcation lesions. EuroIntervention, 2022, 18, 71-82.	1.4	2
511	Timing of statin dose: a systematic review and meta-analysis of randomized clinical trials. European Journal of Preventive Cardiology, 2022, 29, e319-e322.	0.8	2
512	Clinical and Quality-of-Life Outcomes Following Invasive vs Conservative Treatment of Patients With Chronic Coronary Disease Across the Spectrum of Kidney Function. JAMA Cardiology, 2022, 7, 825.	3.0	2
513	Good News from Lake Wobegon. American Journal of Medicine, 2006, 119, 4-5.	0.6	1
514	Does Life-Long Reduction in Low-Density Lipoprotein Cholesterol Reduce the Risk of New-Onset Hypertension?. American Journal of Cardiology, 2006, 98, 1122.	0.7	1
515	Siesta, All-Cause Mortality, and Cardiovascular Mortality: Is there a â€œSiestaâ€•at Adjudicating Cardiovascular Mortality?. Archives of Internal Medicine, 2007, 167, 2143.	4.3	1
516	Î²-Blockers: No longer an option for uncomplicated hypertension. Current Cardiovascular Risk Reports, 2008, 2, 280-285.	0.8	1
517	Simpleâ€Minded Antihypertensive Treatment: Of Assumptions, Potpourri, and Sausages. Journal of Clinical Hypertension, 2009, 11, 702-706.	1.0	1
518	Drug-eluting versus bare-metal coronary stents: where are we now?. Journal of Comparative Effectiveness Research, 2012, 1, 501-508.	0.6	1
519	Fraudulent data: an apology and the fate of angiotensin receptor blockers. BMJ, The, 2013, 347, f5549-f5549.	3.0	1
520	Toward a More Responsible News Media. American Journal of Medicine, 2013, 126, 370-372.	0.6	1
521	Î²-Blocker Use for Patients With or at Risk for Coronary Artery Diseaseâ€”Reply. JAMA - Journal of the American Medical Association, 2013, 309, 438.	3.8	1
522	Dual RAS blockadeâ€”unresolved controversy?. Nature Reviews Nephrology, 2013, 9, 640-640.	4.1	1

#	Article	IF	Citations
523	Authors' reply to Laragh and Sealey. BMJ, The, 2013, 346, f1689-f1689.	3.0	1
524	Reply. Journal of the American College of Cardiology, 2014, 63, 2053.	1.2	1
525	Choosing the Right Coronary Stent in the Modern Era. Current Cardiology Reports, 2014, 16, 469.	1.3	1
526	Eighth Joint National Committee: Evidence Versus Eminence. American Journal of Cardiology, 2014, 113, 2086.	0.7	1
527	Giant Cell Myocarditis: Not Always a Presentation of Cardiogenic Shock. Case Reports in Cardiology, 2015, 2015, 1-4.	0.1	1
528	Reply to Letters Regarding Article, â€œPrognostic Value of Fasting Versus Nonfasting Low-Density Lipoprotein Cholesterol Levels on Long-Term Mortality: Insight From the National Health and Nutrition Examination Survey III (NHANES-III)â€• Circulation, 2015, 131, e473.	1.6	1
529	Choosing between percutaneous coronary intervention and coronary artery bypass graft surgery for nondiabetic patients with multivessel disease. Journal of Thoracic Disease, 2016, 8, 3028-3033.	0.6	1
530	In hypertensive patients with elevated risk of cardiovascular disease, targeting systolic blood pressure to less than 120â€…mmâ€…Hg significantly reduces the rate of fatal and non-fatal cardiovascular events as well as death from any cause. Evidence-Based Medicine, 2016, 21, 101-101.	0.6	1
531	Harnessing the Potential of HumanÂAutologous Stem Cells to TreatÂRefractoryÂAngina. JACC: Cardiovascular Interventions, 2016, 9, 1586-1588.	1.1	1
532	In Replyâ€”The Different Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Mortality. Mayo Clinic Proceedings, 2016, 91, 972-975.	1.4	1
533	Renal denervation: will the Phoenix rise from the ashes?. European Heart Journal, 2017, 38, 3321-3323.	1.0	1
534	Cardiovascular risk stratification after renal transplant: Is SPECT-MPI the answer?. Journal of Nuclear Cardiology, 2017, 24, 304-307.	1.4	1
535	TCT-176 Implantation of Thin-Strut Sirolimus-Eluting Bioresorbable Vascular Scaffold in Patients With De Novo Coronary Artery Lesions: 2-Year Clinical and 6-Month Imaging Outcomes of the MeRes-1 Extend Trial. Journal of the American College of Cardiology, 2019, 74, B175.	1.2	1
536	Meta-Analysis in the Mirror of its Quotations: Science, Scepticism, Scorn, and Sarcasm. European Heart Journal, 2019, 40, 3290-3291.	1.0	1
537	Acute ThrombogenicityÂof SYNERGYÂDrug-Eluting Stent. JACC: Cardiovascular Interventions, 2019, 12, 1676-1678.	1.1	1
538	Response by Bangalore to Letter Regarding Article, â€œNewer-Generation Ultrathin Strut Drug-Eluting Stents Versus Older Second-Generation Thicker Strut Drug-Eluting Stents for Coronary Artery Disease: Meta-Analysis of Randomized Trialsâ€• Circulation, 2019, 139, 2083-2084.	1.6	1
539	Choosing between aspirin or P2Y12 monotherapy after short course of DAPT. American Heart Journal, 2020, 230, 100.	1.2	1
540	Impact of adherence to the hybrid algorithm for initial crossing strategy selection in chronic total occlusion percutaneous coronary intervention. Revista Espanola De Cardiologia (English Ed), 2020, 74, 1023-1031.	0.4	1

#	Article	IF	Citations
541	Imaging and 2â€year clinical outcomes of thin strut sirolimusâ€eluting bioresorbable vascular scaffold: The MeRes â€1 extend trial. Catheterization and Cardiovascular Interventions, 2020, 98, 1102-1110.	0.7	1
542	Decline in the Volume of Structural Heart Procedures in the United States Due to the COVID-19 Pandemic. Structural Heart, 2021, 5, 97-98.	0.2	1
543	Successful transcatheter treatment for very late migration of a transcatheter aortic valve into the left ventricular outflow tract. Catheterization and Cardiovascular Interventions, 2021, 97, 1492-1495.	0.7	1
544	Response by Bangalore et al to Letter Regarding Article, â€œRoutine Revascularization Versus Initial Medical Therapy for Stable Ischemic Heart Disease: A Systematic Review and Meta-Analysis of Randomized Trialsâ€• Circulation, 2021, 143, e809-e810.	1.6	1
545	STEMI outcomes in the era of COVID-19: reaffirmation of an unfortunate reality. EuroIntervention, 2021, 16, 1379-1380.	1.4	1
546	MANAGEMENT OF CLOT IN TRANSIT IN A POST-PARTUM COVID-19 PATIENT. Journal of the American College of Cardiology, 2021, 77, 2920.	1.2	1
547	Salt consumption at a population level remains remarkably steady over time. European Heart Journal, 2021, 42, 2134-2134.	1.0	1
548	Hospital Volume and Outcomes of Coronary Atherectomy. American Journal of Cardiology, 2021, 146, 140-141.	0.7	1
549	Enhancing occupational safety in the X-ray laboratory. Coronary Artery Disease, 2021, Publish Ahead of Print, .	0.3	1
550	Lung Sestamibi Uptake on Myocardial Perfusion Imaging and Outcomes in Chronic Kidney Disease. CardioRenal Medicine, 2021, 11, 67-76.	0.7	1
551	Assumptions and extrapolation. BMJ: British Medical Journal, 2009, 338, b2600-b2600.	2.4	1
552	Abstract 13485: Prevalence and Treatment of â€œBalloon Uncrossableâ€•Coronary Chronic Total Occlusions. Circulation, 2014, 130, .	1.6	1
553	Oral Antiplatelet Therapy Administered Upstream to Patients With NSTEMI. Critical Pathways in Cardiology, 2020, 19, 166-172.	0.2	1
554	The Glass Is at Least Half Full. JACC: Cardiovascular Interventions, 2021, 14, 2350-2352.	1.1	1
555	A Clinical Perspective on Arsenic Exposure and Development of Atherosclerotic Cardiovascular Disease. Cardiovascular Drugs and Therapy, 2023, 37, 1167-1174.	1.3	1
556	Celecoxib and Hypertensionâ€”Insights from the Effect of Celecoxib on Restenosis After Coronary Angioplasty With a Taxus Stent Trial. American Journal of Cardiology, 2008, 101, 1068.	0.7	0
557	Perioperative Î² blockade: the debate continues â€“ Authors' reply. Lancet, The, 2009, 373, 628.	6.3	0
558	Pathway for the Management of Patients Based on Stress Echo Results. , 2009, , 193-200.		0

#	Article	IF	Citations
559	The Changing Paradigm of Stress Echocardiography: Risk Stratification, Prognosis, and Future Directions. Hospital Practice (1995), 2010, 38, 26-39.	0.5	0
560	Rebuttal: What to do for patients who need noncardiac surgery post drug-eluting stent implantation?. Catheterization and Cardiovascular Interventions, 2012, 79, 499-500.	0.7	0
561	Cardiovascular Death and Cancer Deathâ€"Competing Risk?. American Journal of Cardiology, 2012, 109, 1687.	0.7	0
562	The great taboo of nonâ€"infarct-related artery revascularization during primary percutaneous coronary intervention. American Heart Journal, 2013, 166, 611-613.	1.2	0
563	Introduction. Progress in Cardiovascular Diseases, 2013, 55, 465.	1.6	0
564	Combination Antithrombotic Management for Nonâ€"ST Segment Elevation Acute Coronary Syndromes. Interventional Cardiology Clinics, 2013, 2, 553-571.	0.2	0
565	Is Dual Renin-Angiotensin-System Blockade Associated With Increased Risk of Stroke?. JACC: Heart Failure, 2013, 1, 454-457.	1.9	0
566	The Reply. American Journal of Medicine, 2014, 127, e19.	0.6	0
567	TCT-470 Antithrombotic Therapy during Primary Percutaneous Coronary Intervention for Acute Myocardial Infarction: Insights from Direct Comparison and Mixed Treatment Comparison Analysis of Randomized Trials. Journal of the American College of Cardiology, 2014, 64, B138.	1.2	0
568	Dietary salt reduction; further lowering of target lowers blood pressure but may increase risk. Evidence-Based Medicine, 2014, 19, 22-22.	0.6	0
569	The Reply. American Journal of Medicine, 2015, 128, e15-e16.	0.6	0
570	FP328LIPID LOWERING EFFICACY OF ATORVASTATIN IS RELATED TO IMPROVEMENT OF KIDNEY FUNCTION OVER TIME. Nephrology Dialysis Transplantation, 2015, 30, iii178-iii178.	0.4	0
571	2013 ACC/AHA GUIDELINE RECOMMENDATION ON BLOOD CHOLESTEROL REVISITED: PERCENT LDL-C REDUCTION OR ATTAINED LDL-C LEVEL OR BOTH FOR PROGNOSIS?. Journal of the American College of Cardiology, 2015, 65, A1361.	1.2	0
572	Treatment of Patients With Stable Ischemic Heart Diseaseâ€"Reply. JAMA - Journal of the American Medical Association, 2016, 315, 1905.	3.8	0
573	Cognitive Decline, Blood Pressure Control and Variability: A Relentless Downward Spiral?. Journal of the American Medical Directors Association, 2016, 17, 1160-1161.	1.2	0
574	TEMPORAL TRENDS AND OPERATOR VARIATION IN ANTICOAGULANT USE DURING PERCUTANEOUS CORONARY INTERVENTION FOR PATIENTS WITH ACUTE MYOCARDIAL INFARCTION IN THE UNITED STATES. Journal of the American College of Cardiology, 2016, 67, 465.	1.2	0
575	Safety vs Efficacy of Lowering Blood Pressure. JAMA Cardiology, 2017, 2, 1398.	3.0	0
576	Reply. JACC: Heart Failure, 2017, 5, 851.	1.9	0

#	Article	IF	Citations
577	Reply. JACC: Heart Failure, 2018, 6, 890.	1.9	0
578	Overlap in Age at the Time of Elective Percutaneous Coronary Intervention and at Noncardiac Surgery. Journal of the American College of Cardiology, 2018, 72, 1554-1555.	1.2	0
579	When Guideline Authors Ignore Their Own Guidelines. Hypertension, 2018, 72, e19.	1.3	0
580	Age, Cardiovascular Risk, and Blood Pressure Target. Journal of the American College of Cardiology, 2018, 72, 818-819.	1.2	0
581	Following Renal Outcomes With StagingÂin Percutaneous Coronary Intervention Trials. JACC: Cardiovascular Interventions, 2018, 11, 1661-1662.	1.1	0
582	Response to â€œThe Effect of Arteriovenous Fistula on Hard Endpoints Should be Observed Prospectively in Both CKD and Non-CKD Patientsâ€• American Journal of Hypertension, 2019, 32, e2-e2.	1.0	0
583	Letter by Messerli and Bangalore Regarding Article, â€œAssociation of Blood Pressure Measurements With Peripheral Artery Disease Eventsâ€• Circulation, 2019, 139, 1854-1854.	1.6	0
584	Surgical Replacement After Transcatheter Aortic Valve Replacement Due to Device Distortion. Seminars in Thoracic and Cardiovascular Surgery, 2020, 32, 857-859.	0.4	0
585	Updated meta-analysis on the efficacy of genotype-guided antiplatelet therapy versus standard therapy for patients undergoing PCI. Thrombosis Research, 2020, 196, 398-399.	0.8	0
586	Meta-analysis of PCI vs. CABG for left main disease revisited. American Heart Journal, 2020, 229, 178-179.	1.2	0
587	ST-Segment Elevation Myocardial Infarction in the Morbidly Obese. JACC: Cardiovascular Interventions, 2021, 14, 807-808.	1.1	0
588	COVID-19 Myocarditis. Infectious Diseases in Clinical Practice, 2021, 29, e414-e417.	0.1	0
589	Future Perspectives of Left Main Revascularization Trials. American Heart Journal, 2021, 236, 109.	1.2	0
590	Dual-Guide Triple-Kiss Technique for LeftÂMain Trifurcation. JACC: Cardiovascular Interventions, 2021, 14, e139-e141.	1.1	0
591	Elevated C-Reactive Protein Is Associated With Increased Risk of Mortality From Lung Cancer in the United States. Chest, 2014, 146, 592A.	0.4	0
592	Abstract 13000: Trends in Incidence, Invasive Management and Outcomes of Cardiogenic Shock Complicating Non ST-Segment Elevation Myocardial Infarction. Circulation, 2014, 130, .	1.6	0
593	Abstract 15647: Incidence and Outcomes of Hospitalizations Associated With Adverse Effects of Anticoagulation in Therapeutic Use. Circulation, 2014, 130, .	1.6	0
594	The relentless crumbling of the renin-angiotensin system (RAS)-blockade halo. Annals of Translational Medicine, 2016, 4, 321-321.	0.7	0

#	Article	IF	Citations
595	Revascularization Strategies in Chronic Kidney Disease: Percutaneous Coronary Intervention Versus Coronary Artery Bypass Graft Surgery. , 2017, , 317-327.		0
596	Multivessel Coronary Artery Disease. , 2018, , 431-448.		0
597	Is diabetes still a compelling indication for renin-angiotensin-aldosterone system inhibitors?. Cleveland Clinic Journal of Medicine, 2020, 87, 9.1-9.	0.6	0
598	Major infections after bypass surgery and stenting: an overlooked but fatal complication. EuroIntervention, 2020, 15, 1476-1478.	1.4	0
599	The risk of stent thrombosis of dual antithrombotic therapy for patients who require oral anticoagulant undergoing percutaneous coronary intervention: insights of a meta-analysis of randomized trials. Scandinavian Cardiovascular Journal, 2022, , 1-3.	0.4	0
600	Teachable moment or missed opportunity?. European Heart Journal, 2015, 36, 2762.	1.0	0
601	Invasive Management of Acute Myocardial Infarctions During the Initial Wave of the COVID-19 Pandemic. Journal of Invasive Cardiology, 2021, , .	0.4	0
602	Abstract 10596: Telephone-Based Stress Management in Women with Myocardial Infarction: Findings from the Go Red for Women Strategically Focused Research Network. Circulation, 2021, 144, .	1.6	0
603	Revascularization and Survival in Multivessel Coronary Artery Disease in ISCHEMIA. JTCVS Open, 2022, , .	0.2	0
604	Abstract 17: Association Between Age And Health Status In Chronic Coronary Disease With An Initial Invasive Or Conservative Strategy: Insights From The ISCHEMIA Trial. Circulation: Cardiovascular Quality and Outcomes, 2022, 15, .	0.9	0